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Abstract 
 
Neural control of the sleep-wake cycle results from the complex interaction of 
neurotransmitters systems, which arise from anatomically and chemically defined brain 
structures. Serotonergic neurons located in the dorsal raphe nucleus (DRN) are currently 
accepted to be wake-promoting however their precise regulation by other neurotransmitter 
systems during the sleep-wake cycle is currently unknown. The main aim of this study was to 
utilise in vitro and in vivo electrophysiological techniques in order to elucidate the intra-raphe 
regulation of serotonergic neurons. 
 
In vitro, single-unit recordings from putative serotonin (5-HT) neurons revealed that these 
neurons fired spontaneously in acute brain slices taken from mice. Initial pharmacological 
investigations revealed that putative 5-HT neurons in the DRN were under regulatory control 
by α1-adrenoreceptors, 5-HT2 receptors, orexin receptors and histamine receptors.  In vitro, 
patch-clamp studies were performed in order to extend the investigation of 5-HT2, orexin and 
histamine receptors further in the hope of understanding the cellular mechanisms responsible 
for their actions. Most interestingly, histamine produced a large inward current, depolarisation 
and excitation of putative 5-HT neurons in the DRN. Histamine was shown to mediate its 
effects predominantly via the H1 receptor subtype and furthermore this receptor was 
observed to be constitutively active in the acute brain slice.  
 
In vivo, single unit recordings from putative 5-HT neurons were performed in order to assess 
the role of the H1 receptor further. Recordings were made from the DRN of anaesthetised, 
head-restrained rats. Pharmacological inhibition of H1 receptors reduced the firing of putative 
5-HT neurons, confirming the functional activity of these receptors in the intact brain. In order 
to investigate the significance of H1 receptor blockade on the sleep-wake cycle, 
electroencephalogram (EEG) recordings were performed. EEG recordings revealed that 
blocking H1 receptors caused a significant increase in the amount of non-rapid eye movement 
(NREM) sleep. The data reported here could have important clinical implications in the 
discovery of novel sleep therapies which target the serotonergic and/or the histaminergic 
system.
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Chapter 1: 
Introduction 
2 
 
 
1.1 The sleep-wake cycle 
 
Sleep is a universal phenomenon which has been observed in almost every animal species 
studied. In humans it is essential for our cognitive and physical wellbeing (Alhola & Polo-
Kantola, 2007; Neu et al., 2010), however a precise understanding of how and why we sleep is 
far from complete. Sleep is defined behaviourally by a number of criteria including: reduced 
motor activity, decreased response to stimulation, stereotypic postures, and relative ease of 
reversibility (distinguishing it from coma, hibernation and anaesthesia) (Rechtschaffen & 
Siegal, 2000). The transition from waking to sleep is accompanied by obvious changes to the 
electrical activity of the brain, most commonly recorded by electroencephalogram (EEG) 
(Figure 1, top). During wakefulness the cortical EEG displays high-frequency, low amplitude 
waves however as an individual “falls” asleep the EEG transitions progressively into slow-
frequency, high voltage waves representing non-rapid eye movement or slow-wave sleep 
(NREM or SWS) (Dement & Kleitman, 1957). The high-frequency, low amplitude activity is 
associated with behavioural activation and is often referred to as “desynchronised” activity, 
whereas the slow-frequency, high amplitude EEG activity reflects the synchronous alternation 
between firing and inactivity of a large population of neurons in the brain and is often referred 
to as “synchronised” activity (Steriade, 1994). The changes to the EEG are observed in humans 
and rodents however the timing is noticeably different. In humans the changes take anywhere 
from 10 seconds to a minute, whereas in rodents these changes can occur over a few seconds 
or less (Merica & Fortune, 2004; Tanaka et al., 2000). During NREM sleep the EEG is 
characterised by progressively slower frequencies and higher amplitude activities, moving 
from theta waves (4-8Hz) through to delta waves (0.5-4Hz). In humans NREM sleep is divided 
into 4 stages (I, II, III and IV: corresponding to the depth of sleep) whereas in rodents it is 
divided into 2 stages (NREM-1 and NREM-2), mimicking stages I-II and III-IV, respectively 
(Wafford & Ebert, 2008). In humans a typical NREM bout lasts from 40 minutes to an hour, 
whereas in rodents this is much shorter, typically lasting for a few minutes. Across four 
mammalian species including human and rat, the duration of sleep bouts positively correlated 
with the metabolic rate per unit body mass (Lo et al., 2004). The EEG then transitions from 
NREM into REM sleep, with lower voltage, higher frequency activity. During REM sleep, there 
is a complete loss of skeletal muscle tone, except those used for eye movements and 
breathing. REM sleep is most often accompanied by active dreaming however less lively  
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Figure 1.0 Sleep-wake parameters and measurements. Top: Electroencephalogram (EEG) 
activity of the brain during each stage of sleep: awake (high-frequency, low amplitude waves), 
stage 1 (theta waves), stage 2 (sleep spindles), stage 3 (0.5-4Hz waves), stage 4 (delta waves), 
REM (higher-frequency, low amplitude). Bottom: Sleep architecture over 7 hours showing the 
transition from wakefulness through to REM sleep. Note brief awakenings can occur. Adapted 
from Wafford et al, 2008 with permission.  
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dreaming is noted to occur during NREM sleep (Aserinsky & Kleitman, 1953; Foulkes, 1962). 
Over the sleep period (12-18 minutes in rats and about 90 minutes in humans) an ordered 
cycle is usually maintained from NREM to REM to wake however switching may occur between 
NREM and REM and brief awaking can interrupt the cycle (Figure 1.0, bottom). 
 
1.1.1. Two-process model of sleep 
 
Sleep propensity is governed by two distinct processes: a circadian regulator (Process C), 
defining the diurnal rhythm and a homeostatic regulator (Process S), defining the interaction 
between wake time and sleep time (Borbély, 1982; Daan et al., 1984). Homeostatic regulation 
of sleep refers to the observation that sleep is prolonged and often more profound after long 
periods of waking. An increase in the amount of slow-wave (delta) EEG during subsequent 
compensatory NREM sleep opposes sleep fragmentation and hence improves sleep continuity. 
The nature of homeostatic drive for sleep has been the subject of much consideration, with 
some researchers suggesting that the build-up of a regulatory “sleep-factor” (possibly 
adenosine) promotes sleep (Strecker et al., 2000). Circadian regulation of sleep originates in 
the suprachiasmatic nuclei (SCN) and is often referred to as the ‘biological clock’ (Easton et al., 
2004). Circadian timing originates from the hierarchy of circadian oscillators in the SCN which 
receive light information from the retinohypothalmic tract entraining the clock to an almost 
24-hour cycle of activity (Reppert & Weaver, 2002). Positive and negative transcriptional 
feedback loops drive repetitive rhythms in RNA and protein levels of important clock genes 
e.g. Clock, Bmal, Per1 and Per2. Peripheral molecular clocks located in the kidney, liver and 
pancreas are controlled by the central SCN clock in order to align metabolic activities with 
environmental conditions (Reppert & Weaver, 2002). Over time, the two-process model of 
sleep has been extended by some to include a third process (Process W). The wake 
component (W) represents reduced levels of alertness normally observed after waking, also 
referred to as “sleep inertia” (Folkard & Åkerstedt, 1992). Models of sleep have been used by 
neurobiologists to development mathematical models to evaluate the impact of shift work 
and travel schedules (Åkerstedt, 1998; Åkerstedt & Folkard, 1997). 
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1.1.2 Wake-promoting networks 
 
The neural control of the sleep-wake cycle results from the complex interaction of transmitter 
systems which arise from anatomically and chemically-defined structures within the brain. 
Current models of the arousal system are based on seminal studies which demonstrated that 
the rostral brainstem (i.e. midbrain and pons) contains an “ascending reticular activating 
system” responsible for producing EEG desynchrony and arousal (Moruzzi & Magoun, 1949). 
Subsequent studies have revealed that the cell groups at the mesopontine junction 
responsible for arousal consist of cholinergic and monoaminergic neurons (Levey et al., 1987; 
Rye et al., 1987). Cholinergic neurons in the pedunculopontine and laterodorsal tegmental 
nuclei (PPT and LDT) provide major innervation from the mesopontine junction to the thalamic 
relay nuclei and reticular nucleus as well as the lateral hypothalamus and basal forebrain 
(Figure 1.1.) (Hallenger et al., 1987; Satoh et al., 1986). Cholinergic nuclei are heterogeneous, 
with neurons exhibiting high rates of firing during wakefulness (“wake-on”) and also during 
REM sleep (“REM-on”) (Steriade et al., 1990). Monoaminergic cell groups at the mesopontine 
junction which project to the forebrain include noradrenaline from the locus coeruleus (LC) 
and serotonin (5-HT) from the dorsal and median raphe nuclei (DR and MnR) (Saper et al., 
2010). In addition, histaminergic neurons from the tuberomamillary nucleus (TMN) and 
dopaminergic neurons from the ventral tegmentum area (VTA) and substantia nigra (SN) also 
project to the forebrain (Saper et al., 2010). These monoaminergic cell groups innervate the 
lateral hypothalamus, basal forebrain and cerebral cortex (Krout et al., 2002). In addition they 
also innervate the thalamus, specifically targeting the intralaminar and reticular nuclei (Krout 
et al., 2002; Vertes, 1991). In general, neurons from these nuclei fire at greater rates during 
wakefulness, decrease activity during NREM sleep and cease firing during REM sleep (Sakai et 
al., 2011; Takahashi et al., 2006, 2010). One major exception is the dopaminergic neurons 
which tend not to change their firing across the sleep-wake cycle (Miller et al., 1983).  
 
Another important arousal system is located in the lateral hypothalamus, just dorsal and 
rostral to the histaminergic neurons of the TMN (Bernardis & Bellinger, 1996). Neurons in the 
lateral hypothalamus contain orexin neuropeptides (orexin-A and -B, also known as 
hypocretin-1 and -2). Orexin neurons send axons to the entire cerebral cortex, in addition to 
the brainstem and basal forebrain (Nambu et al., 1999; Peyron et al., 1998a). Importantly 
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orexin neurons innervate the LC, TMN, DRN as well LDT and thalamus (Peyron et al., 1998a). 
Orexin neurons exhibit a similar firing pattern to the other arousal nuclei, firing at greater 
frequencies during sleep, slowing during NREM and falling silent during REM sleep (Takahashi 
et al., 2008). Orexin-directed lesions (Gerashchenko et al., 2001) and orexin receptor “knock-
out” mouse (Chemelli et al., 1999) studies have revealed a role for orexin neurons in the sleep 
condition narcolepsy. The apparent role of orexin in narcolepsy suggests that the role of these 
neurons might be to sustain wakefulness especially via the excitation of the other arousal 
systems. The basal forebrain provides an additional sub-cortical population of arousal-
promoting neurons. Many basal forebrain neurons contain either acetylcholine, gamma-
amino-butyric acid (GABA) or glutamate (Manns et al., 2001). Many of these basal forebrain 
neurons are wake-active and thought to produce EEG desynchronisation via activation 
(acetylcholine and glutamate) and inhibition (GABA) of cortical circuits (Henny & Jones, 2008; 
Jones, 2004). The thalamus plays an important role in gating the transmission between 
subcortical/brainstem nuclei and the cortex. Thalamocortical transmission is modulated via 
GABAergic neurons in the reticular nucleus which have an inhibitory influence over the 
thalamic relay nuclei (Steriade, 2005). Arousal nuclei, including serotonergic and histaminergic 
neurons, innervate the reticular nucleus, which may represent an important mechanism by 
which arousal nuclei modulate activity within thalamocortical circuits (Manning et al., 1996; 
Rodriguez et al., 2011). 
 
1.1.3 NREM sleep-promoting networks    
 
Between 1917 and 1931 the neurologist Dr Constantin von Economo reported that patients 
suffering from encephalitis lethargica had symptoms which manifested as either profound 
insomnia, or somnolence (reviewed by Triarhou, 2006). He discovered that patients with 
lesions in the pre-optic area near the rostral end of the third ventricle presented with 
insomnia. It was a further half a century before the exact population of sleep-promoting 
neurons was discovered in the ventrolateral pre-optic nucleus (VLPO) (Sherin et al., 1996). 
VLPO neurons were shown to contain the inhibitory neurotransmitters GABA and galanin, the 
majority of which fire fastest during NREM and REM sleep (Takahashi et al., 2009). 
Furthermore, it was demonstrated that the VLPO contained a dense core of sleep-active 
neurons that projected to the TMN and a diffuse shell of neurons that projected to the DRN 
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and LC (Figure 1.1) (Lu et al., 2002; Sherin et al., 1998; Steininger et al., 2001). A second 
population of sleep-active, GABAergic neurons has been discovered in the median preoptic 
nucleus (MnPO) (Gong et al., 2000 and 2004). Interestingly, MnPO neurons have been shown 
to fire in advance of sleep, whereas VLPO neurons only fire during sleep (Szymusiak et al., 
1998). Given that the MnPO provides a robust input into the VLPO it has been suggested that 
MnPO may drive the activity of the VLPO (Chou et al., 2002). VLPO neurons receive reciprocal 
inputs from a number of the arousal nuclei including the TMN, DRN and LC, whereas MnPO 
neurons receive only a sparse input (Saper & Levisohn, 1983; Uschakov et al., 2007). In vitro 
recordings have revealed that VLPO neurons are inhibited by acetylcholine, noradrenaline, 
dopamine and serotonin (Gallopin et al., 2000, 2004). This reciprocal inhibition between sleep-
active VLPO neurons and wake-active monaminergic neurons has been proposed to form a 
“flip-flop switch” (Saper et al., 2001). According to this model, during sleep VLPO neurons 
would fire at greater rates and inhibit the monoaminergic nuclei, therefore disinhibiting and 
reinforcing their own firing. Conversely during wakefulness monoaminergic neurons would fire 
at higher frequencies and inhibit the VLPO neurons, thus dis-inhibiting their own firing (Figure 
1.2). 
 
 1.1.4 REM sleep-promoting networks 
 
Just prior to and during REM sleep, neurons in the pons, the lateral geniculate nucleus, and 
the occipital cortex fire bursts of high-voltage spikes (Lim et al., 2007). These ponto-geniculo-
occipital (PGO) spikes, or waves, are time locked to bursts of firing in the PPT and LDT nuclei 
(Sakai & Jouvet, 1980). As discussed above, neurons in the LC, DRN and TMN are virtually 
silent during REM sleep. This reciprocal relationship hinted that cholinergic neurons from PPT 
and LDT may interact with the monoaminergic cell groups to regulate the switch between 
NREM and REM sleep. This suggestion was supported by the demonstration that application of 
cholinergic compounds (e.g. agonists and cholinesterase inhibitors) to the mesopontine area 
can produce REM sleep, whereas application of compounds that activate monoaminergic cell 
groups (e.g. MAO inhibitors and SSRIs) can inhibit REM sleep (Datta, 1997; Gervasoni et al., 
2002; Luppi et al., 2007). A number of lesion studies have questioned the ability of these 
neurons to switch states between NREM and REM sleep, as destruction of the PPT or LDT had 
minimal effects on REM sleep (Lu et al., 2006). Therefore while these systems appear to 
modulate REM sleep, they are not likely to be involved in the switching mechanism  
8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. Components of the sleep-wake cycle. During wakefulness, cholinergic neurons 
from the LDT/PPT (yellow) provide the major innervation of the thalamus. A second pathway 
(red) arising from monoaminergic neurons from the brainstem provides direct input to the 
hypothalamus, basal forebrain and cortex. The orexin neurons of the LH maintain activity in 
the ascending arousal system. During sleep, GABAergic and galanergic neurons (purple) from 
the VLPO and MnPO project to and inhibit the ascending arousal centres. Taken from Saper et 
al., 2005 with permission.   
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Figure 1.2. The sleep-wake switch. During wakefulness monoaminergic nuclei (red) inhibit 
GABAergic/galanergic VLPO nuclei (purple), thereby removing the inhibition of monoaminergic 
cells (LC, TMN and raphe) and cholinergic cells (LDT and PPT). Orexin neurons (green) act 
primarily to stabilise monoaminergic tone during wakefulness. During sleep VLPO neurons 
inhibit monoaminergic nuclei, thereby relieving their own inhibition. VLPO neurons also inhibit 
orexin neurons, further reinforcing monoaminergic inhibition during sleep. This mutual 
inhibition and excitation between nuclei forms a flip-flop switch, enabling sharp transitions 
between states, but is relatively unstable. Taken from Saper et al., 2005 with permission.   
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(Saper et al., 2010). Fos immunoreactivity studies have been utilised in order to try and 
discover the identity of the REM-promoting neurons. These studies have highlighted a number 
of cell groups in the pons that are active during REM sleep, including neurons in the 
sublaterodorsal nucleus (SLD), the precoeruleus region and medial parabrachial nucleus 
(Boissard et al., 2002; Lu et al., 2006). Retrograde tracers have revealed that GABAergic 
neurons from the ventrolateral periaqueductal grey (vlPAG) and LPT have a mutually inhibitory 
relationship with GABAergic neurons in the SLD (Lu et al., 2006) leading these authors to 
hypothesise that this mutual inhibition is the basis for NREM-REM sleep switching. Neurons 
that produce the peptide, melanin-concentrating hormone (MCH) are located in the lateral 
hypothalamus, in close proximity to orexin neurons (Bittencourt et al., 1992). These MCH 
neurons fire fastest during REM sleep and many neurons also contain GABA, endowing them 
with the ability to inhibit target neurons (Hassani et al., 2009; Jego et al., 2013). Given the 
wide spread projection of MCH neurons in the brain, including to the DRN and LC, it will be 
important in future studies to investigate the precise role for these neurons in REM sleep.  
 
1.2 Serotonin 
 
Serotonin, or 5-hydroxytryptamine (5-HT), is a biogenic monoamine with diverse effects in the 
central nervous system (CNS) as well as the periphery (Mohammad-Zadeh et al., 2008). It is 
biosynthetically derived from the essential amino acid tryptophan in a two-step enzymatic 
process. Tryptophan is first hydroxylated to 5-hydroxytryptophan (5-HTP) by tryptophan 
hydroxylase (the rate-limiting step) and then 5-HTP is decarboxylated to form 5-HT (Clark et 
al., 1954; Fitzpartick, 1999). Two isoforms of tryptophan hydroxylase have been identified, one 
which is expressed in the gut (tph1) (Walther et al., 2003) and one that is expressed exclusively 
in the brain (tph2) (Patel et al., 2004). Within the CNS, 5-HT is synthesised and stored in 
presynaptic terminals (serotonergic neurons, catecholaminergic neurons and the pineal 
gland). In the periphery, 5-HT storage is limited to enterochromomaffin cells and platelets 
(Rapport et al., 1948; Weiner & Undenfriend, 1957). The concentration of 5-HT in tissues is 
dependent upon the rate of synthesis and the rate of metabolism. The primary metabolic 
pathway for serotonin is via metabolism by monoamine oxidase (MAO) to 5-
hydroxyindoleacetic acid (McIsaac & Page, 1959). In the CNS, neuronal depolarization causes 
the release of 5-HT into the synaptic cleft. Once in the synapse, 5-HT can bind to postsynaptic 
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5-HT receptors or presynaptic 5-HT autoreceptors to exert its actions (Fink & Göthert, 2007; 
Cerrito & Raiteri, 1979a, 1979b). The selective serotonin transporter (SERT) located on the 
presynaptic membrane removes 5-HT from the synaptic cleft (Ravna et al., 2009). Once inside 
the neurons, 5-HT is packaged back into synaptic vesicles where it is protected from 
metabolism. 5-HT remaining in the cytosol is rapidly metabolised by MAO (Jonnakuty & 
Gragnoli, 2008; Molinoff & Axelrod, 1971). 
 
1.2.1 Serotonin receptors 
 
The diverse effects of 5-HT are mediated via 5-HT receptors. There are currently seven families 
of 5-HT receptors (designated 5-HT1-7) that are organised into fourteen subtypes, representing 
one of the most complex families of neurotransmitter receptors. The Receptor Nomenclature 
Committee of the International Union of Pharmacology (NC-IUPHAR) has proposed a 
classification scheme of 5-HT receptors based on pharmacological, transductional and 
structural information (Alexander et al., 2011). With the exception of the 5-HT3 receptor, 
which is a ligand-gated ion channel, all 5-HT receptors are members of the G-protein coupled 
receptor (GPCR) superfamily. The NC-IUPHAR classifies serotonin GPCRs into distinct classes 
with corresponding subtypes: 5-HT1 (5-HT1A, B, D, e, F), 5-HT2 (5-HT2A, B, C), 5-HT3 (5-HT5a, b), 5-HT4, 
5-HT6 and 5-HT7 subtypes. This classification includes receptors which have been generated by 
alternative splicing of single genes (5-HT4, 5-HT7) and editing of the receptor RNA (5-HT1B, D). 
Within a given receptor subtype class the overall amino acid sequence homology ranges 
between 40 and 63%, while the sequence homology between the different families ranges 
between 25 and 39% (Hoyer et al., 2002).  
 
1.2.2 G-protein coupled receptors 
 
GPCRs consist of seven transmembrane-spanning elements with prototypic domains 
determining agonist binding specificity and activation (Kobilka, 2007). The 5-HT GPCRs are 
classified as “type A”, rhodopsin-like receptors (Fredriksson et al., 2003). GPCRs transduce 
signals by activating one or more heterotrimeric G proteins which are composed of one α, β 
and γ subunit. G proteins are divided into four main classes based on the primary sequence 
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similarity of the Gα subunit: GαS, Gαi, Gαq and Gα12 (Oldham & Hamm, 2008). Each Gα subunit 
contains a GTPase domain which hydroylses GTP. Guanine nucleotide exchange leads to the 
dissociation of subunits from the receptor yielding a Gα-GDP monomer and a tightly 
interacting Gβγ dimer. These receptor-free monomer and dimer elements can modulate the 
activity of other intracellular proteins until the inactive form of the Gα subunit (Gα-GDP) is 
regenerated (Oldham & Hamm, 2008). GPCRs were classically thought to function as 
monomeric units however in recent years dimer/oligomer formation has been reported for 
many different GPCRs (Gurevich & Gurevich, 2008). The advent of new techniques including 
immunoprecipitation and resonance energy transfer has enabled researchers to propose that 
5-HT1A, 5-HT1B, 5-HT1D, 5-HT2C and 5-HT4 receptors form functional dimers (Herrick-Davis, 2004; 
Salim et al., 2004). The precise physiological significance of 5-HT receptor dimerisation is still 
unknown however it is speculated that dimerisation of GPCRs would enable ligand selectivity 
and/or activation of alternative intracellular pathways (Herrick-Davis, 2013).    
 
A number of theoretical kinetic models have been developed in order to quantify the 
nonlinear coupling between receptor occupancy and response. In 1965 Monod, Wyman and 
Changeux proposed a model (referred to as the MWC model) that described the properties of 
“allosteric systems” (Monod et al, 1965). This model proposed that a receptor reversibly 
adopts two “states” and each state has a different affinity for the “allosteric” ligand. The 
sigmoidal nature of oxygen binding to haemoglobin and nicotinic cholinergic-mediated Na+ 
influx and depolarization represent two processes consistent with this model (Karlin, 1967). 
The MWC model can be categorized as a “two-state model” where the two states of the 
receptor are described as: the inactive state (R) and the active state (R*) (Leff, 1995). In the 
absence of bound ligand the level of basal receptor activity is determined by the equilibrium 
between R and R* (Figure 1.3). The profile of a ligand can be characterized by its affinity for 
the receptor and intrinsic activity (efficacy). Agonists display positive intrinsic activity by 
binding to the receptor and stabilising R*.  Partial agonists display varying degrees of affinity 
and intrinsic activities and produce a submaximal response. Interestingly, receptors can 
display spontaneous (constitutive) activity independent of ligand activation. Certain ligands 
can bind to these spontaneously active receptors and appose partial or full agonists by shifting 
the equilibrium from R* to R. These ligands are termed “inverse agonists” as they 
preferentially stabilize the receptor in its inactive (R) state and therefore have negative 
intrinsic activity.  
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Neutral antagonists do not possess intrinsic activity and therefore oppose the effects of 
agonists by preventing agonist binding and receptor activation.  If receptors do not display 
spontaneous activity the same inverse agonist could behave as a competitive antagonist. 
Neutral antagonists lack intrinsic activity and can block actions produced by agonists and 
inverse agonists (Khilnani & Khilnani, 2011).  
 
1.2.3 GPCRS and inverse agonism 
 
As eluded to above, some receptors can spontaneously interact with G-proteins to initiate 
GTPase activity in the absence of bound ligands. This constitutive activity can be inhibited in 
vitro by the addition of inverse agonists (with either partial or full activity) whose activity 
opposes that of agonists. Experimental methods to detect constitutive receptor activity are 
based on the quantification of ligand affinity at R and R* (with binding assays) on the 
modulation of GTP binding and hydrolysis. Receptor agonists that activate receptors increase 
basal effector activity whereas inverse agonists decrease basal GPCR activity. Therefore 
spontaneous activity of GPCRs can be demonstrated by measuring cAMP levels, GTPase 
activity or IP3 production in the presence of inverse agonists. Constitutive GPCR activity was 
first demonstrated at δ-opioid receptors (Costa & Hertz, 1989) and more recently in 
benzodiazepine receptors (Braestup et al., 1982) and 5-HT receptors (Herrick-Davis et al, 
2000). It is now well recognized that many conventional GPCR antagonists (including 
antihistamines) are in fact inverse agonists. Constitutive activity may be present in native or 
mutated strains and such receptors may be under- or over-active leading to inherited diseases 
(Khilnani & Khilnani, 2011). 
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Figure 1.3. Schematic of ligand-receptor binding. Agonists bind to receptors, stabilize R* and 
display positive intrinsic activity. Neutral antagonists have equal preference for R and R* 
states, lack intrinsic activity and block the effects of either agonists or inverse agonists. Inverse 
agonists stabilize R and decrease basal receptor activation.  
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1.2.4 Signal transduction of 5-HT receptor subtypes 
 
5-HT GPCRs bind to a number of different heterotrimeric G proteins to exert their effects. 
Receptors of the 5-HT1 class couple preferentially, although not exclusively, to Gi/o. Activation 
of Gi/o leads to inhibition of adenylate cyclase and reduced production of cyclic adenosine 
monophosphate (cAMP) (Hoyer et al., 2002). cAMP is an intracellular messenger that interacts 
with numerous targets including protein kinase A and cyclic nucleotide-gated ion channels 
(Nichols & Nichols, 2008). 5-HT1A receptors are both located pre- and post-synaptically and are 
expressed on various neurons throughout the CNS (Aznavour et al., 2006; Palchaudhuri & 
Flugge, 2005). Activation of 5-HT1A receptors in either location leads to neuronal 
hyperpolarization and reduced firing. Pre-synaptic 5-HT1A autoreceptors in the DRN have been 
shown to mediate neuronal hyperpolarisation via G-protein coupled K+ channels (Sprouse & 
Aghajanian, 1987). 5-HT1B receptors are localised on axon terminals (Riad et al., 2000) where 
they can function as presynaptic heteroreceptors on non-serotonergic neurons or presynaptic 
autoreceptors on serotonin neurons (Sari, 2004). There has only been limited functional 
evidence of 5-HT5 receptors in the brain (Goodfellow et al., 2012) and it is currently thought 
that 5-HT5 receptors, like 5-HT1, couple negatively to adenylate cyclase. However the 
development of selective antagonists and knock-out mice should enable a better 
understanding of these receptors in the future.  Receptors of the 5-HT2 class couple 
preferentially to Gq/11. Activation of Gq/11 leads to an increase in inositol phosphate production 
and an increase in cytosolic Ca2+ levels (Hoyer et al., 2002). 5-HT2 receptors have widespread 
expression in the brain (McKenna & Saavedra, 1987; Pazos et al., 1985). 5-HT2A/2C receptors are 
the target of many hallucinogen drugs including DOI (Krebs-Thomson et al., 1998) while 5-HT2B 
receptors play an important role during development, especially in the co-ordination of brain 
and heart formation (Nebigil et al., 2001). Receptors of the 5-HT4, 5-HT6 and 5-HT7 classes 
couple positively to Gs  and promote the formation of cAMP (Hoyer et al., 2002). In contrast to 
all of the other 5-HT receptors, the 5-HT3 is a ligand gated ion channel.  The 5-HT3 receptor 
belongs to the cysteine-loop transmitter-gated receptor superfamily, which includes the 
GABAA receptor, glycine receptor, nicotinic acetylcholine receptor and the Zn
2+ activated ion 
channel (Boess & Martin, 1994; Davies et al., 2003). 5-HT3 receptors are located both pre- and 
post-synaptically throughout the brain where they trigger the depolarization of target cells via 
the opening of a nonselective cationic channel (Peters et al., 2010).  
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1.3 The dorsal raphe nucleus (DRN) 
 
The distribution of brainstem serotonergic neurons in the rat brain has been elegantly 
discerned by histochemical fluorescence (Dahlstrom & Fuxe, 1964). The localisation of 
serotonergic cell bodies and axons was classified into 9 clusters: B1-B9, with the numbers 
indicating caudal-rostral order of the nuclei. The dorsal raphe nucleus (DRN), comprising of 
clusters B6 and B7, contains the largest group of serotonin neurons in the brainstem 
(Descarries et al., 1982; Vertes & Crane, 1997). The DR is located in the rostral pontine and 
caudal midbrain tegmentum and can be divided into several subregions based on 
cytoarchitectonic grounds, including the rostral, caudal (DRC), dorsal (DRD), ventral (DRV), 
ventrolateral (DRVL), and interfascicular (DRI) parts (Lowry et al., 2008). Serotonergic neurons 
are located throughout the rostral-caudal axis of the DRN, in all subdivisions of the DRN 
(Crawford et al., 2010). However, they predominate along the midline of the dorsal, rostral, 
and ventral subdivisions of the DRN (Abrams et al., 2004). Developmentally, by day 15 of 
gestation, serotonergic neurons can be observed throughout all subdivisions of the rat DRN 
(Jacobs & Azmita, 1992; Lauder & Bloom, 1974).  
 
1.3.1 Morphology and neurochemistry of DRN 5-HT neurons 
 
In the rat DR four cell types are observed: small and round, medium-sized and 
fusiform/bipolar, large and fusiform, and very large and multipolar (Steinbusch. 1981). These 
neurons are topographically organised within the different subdivisions of the DR, suggesting 
the possibility of functional differences of 5-HT neurons across the DR based on their 
morphology (Abrams et al., 2004). In addition to regional differences in the morphology of 
serotonergic neurons, immunohistochemical studies have demonstrated that topographically 
organised subpopulations of serotonergic neurons are chemically diverse. Serotonin is the 
major neurotransmitter in the DR (accounting for 30-70% of neurons, depending on the 
species) however serotonergic neurons have been shown to co-express different 
neurotransmitters and neuropeptides. In the rat, 5-HT neurons co-express the vesicular 
glutamate transporter 3 (VGLUT3) (Fermeau et al., 2002; Commons, 2009), the GABA 
synthesizing enzyme glutamic acid decarboxylase 67 (GAD67) (Shikanai et al., 2012), nitric 
oxide synthase, galanin (Xu & Hökfelt, 1997), and corticotropin-releasing factor (CRF) 
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(Commons et al., 2003). In the mouse, 5-HT neurons display a more restrictive neurochemical 
diversity, with neurons co-expressing GAD67, VGLUT3 and CRF (Fu et al., 2010).  
 
1.3.2 Efferent and afferent projections of the DRN 
 
Efferent outputs from the DR extend throughout the entire brain and provide the major 
source of 5-HT in the forebrain. Efferent projections of serotonergic neurons from DRN display 
a topographic organization along the rostral-caudal axis, with neurons located more rostrally 
projecting to more rostral areas of the brain and neurons located more caudally projecting to 
more caudal areas (Abrams et al., 2004). The DRN projects along three ascending pathways: 
the dorsal, medial and ventral pathways (Michelson et al., 2007). These pathways reach a 
multitude of targets throughout the brain including the thalamus, hypothalamus, basal 
forebrain and cortex, all of which play an important role in regulating sleep-wake cycle 
(Vertes, 1991). In addition four descending projections leave the DRN (Michelson et al., 2007), 
which project to and innervate the locus coeruleus, mesencephalic reticular formation, 
predunculopontine tegmental nucleus, laterodorsal tegmental nucleus and pontine raphe 
nucleus (Vertes & Kocsis, 1994). Furthermore, individual serotonergic neurons can give rise 
collateralized efferents capable of innervating multiple brain regions, enabling the DRN to 
integrate modulation of distinct but functionally related brain regions (Waselus et al., 2011). 
 
Anatomically and neurochemically diverse axons innervate and regulate the neuronal activity 
of DRN neurons. Of note, anatomical studies have demonstrated projections to the DRN from 
all of the major arousal systems (Lee et al., 2004; 2005a,b). These afferent fibers project to the 
DRN in a highly topographical order. Retrograde tracing has shown the DRN receives a highly 
robust histaminergic innervation from the TMN (Lee et al., 2005a), orexinergic projection from 
the lateral hypothalamus (Lee et al., 2005b), noradrenergic input from the locus coeruleus 
(Lee et al., 2004) and cholinergic systems (Woolf & Butcher, 1989). Few studies have examined 
the projections of arousal pathways to specific subdivisions of the DRN. Noradrenergic 
neurons project to the DRD, DRVL, DRI and DRC (Kim et al.,2004) and orexinergic neurons 
project to the DRD, DRVL and DRC (Lee et al., 2005b). In addition, glutamatergic and 
GABAergic neurons from various brain regions innervate the DRN. The medial prefrontal 
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cortex (PFC) provides the major glutamatergic input to each subdivision of the DRN with 
subcortical regions also providing inputs (Lee et al., 2003). GABAergic projections to the DRN 
arise from the lateral hypothalamus, preoptic area (an important sleep center) and also from 
the surrounding periaqueductal grey (Gervasoni et al., 2000). A recent study utilised array 
tomography immunofluorescence to demonstrate that GABA-containing axons are organised 
in a “synaptic triad” with glutamatergic axons and serotonergic neurons in the DRN (Soiza-
Reilly et al., 2013).   
 
1.3.3 Intra-raphe projections  
 
 
Important neural connections exist between serotonergic neurons in different parts of the 
raphe complex. The DRN gives rise to a robust projection to the median raphe (MnR) (Vertes & 
Kocsis, 1994). Functional interactions also exist between neighbouring cell groups in the DRN. 
Retrograde tracing studies have demonstrated a connection between the DRV and 
DRVL/VLPAG region (Peyron et al., 1998b). Selective lesion of serotonergic neurons in the 
DRVL/VLPAG region led to an increase in tryptophan hydroxylase (TPH) mRNA expression 
within the DRV region, suggesting a tonic inhibitory role for DRVL/VLPAG neurons (Ljubic-
Thibal et al., 1999). Intra-raphe, GABAergic interneurons have been demonstrated to synapse 
directly with serotonergic neurons (Allers & Sharp, 2003; Fu et al., 2010; Gervasoni  et al., 
2000; Jankowski & Sesack, 2004) providing a local inhibitory feedback circuit. There is 
tentative evidence to suggest glutamatergic interneurons may exist within the DRN 
(Commons, 2009) however further immunohistochemical work is required to confirm this.  
    
1.3.4 Physiology of serotonergic neurons in the DRN 
 
Early extracellular single-unit recordings from neurons within the DRN of anaesthetized rats 
revealed a population of neurons exhibiting a slow and regular firing pattern (Aghajanian et 
al., 1968). These slow, rhythmically firing neurons were later confirmed to be serotonergic by 
intracellular recording combined with Falck-Hillarp histochemical fluorescence (Aghajanian & 
Vandermaelen, 1982a; Falck et al. 1982). Serotonergic neurons in the DRN demonstrate a 
rhythmic, bi- or tri-phasic, wide action potential (2-4ms) with a pronounced post-spike after-
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hyperpolarisation and depressant response to 5-HT (Vandermaelen & Aghajanian, 1983; 
Williams et al., 1988). These pharmacological and electrophysiological characteristics made it 
possible to identify serotonin neurons in vitro and in vivo, and over time they became 
accepted hallmarks of serotonergic neuronal identity.  
An early study performed with freely moving cats identified two subtypes of serotonergic 
neurons based on their state-dependent and independent firing across the sleep-wake cycle 
(Rasmussen et al., 1984). Type I neurons fired at relatively high frequencies during active 
wake, decreased firing during quiet waking and SWS and virtually ceased firing during 
paradoxical (REM) sleep. Whereas type II neurons maintained a relatively constant firing rate 
irrespective of the behavioural state. Type I neurons were distributed throughout the DRN, 
however type II neurons were shown to be localised to the interfascicular subdivision of the 
DRN (Rasmussen et al., 1984). More recently a study has extended this classification of 
serotonergic neurons further, describing six different subtypes of neurons (Sakai & Crochet, 
2001). Serotonergic neurons were classified into two typical groups (types I-A and I-B) and four 
atypical groups (types I-C, II-A, II-B and II-C), according to differences in firing patterns during 
the sleep-wake cycle. Typical neurons (similar to type I described previously) discharged 
regularly at a high rate during waking, progressively slower rates during SWS, and ceased firing 
either during SWS with PGO waves and paradoxical sleep (type I-A), or only during paradoxical 
sleep (type I-B). Typical neurons were evenly distributed in the DRN. Atypical neurons 
displayed distinct firing pattern, either exhibiting sustained tonic activity during paradoxical 
sleep (types I-C and II-C), or firing at greater frequencies during SWS, with suppression of firing 
during both waking and paradoxical sleep (type II-B). Atypical neurons were unevenly 
distributed in the DRN. This study recorded from a large sample of serotonergic neurons from 
the DRN and for the first time suggested a high degree of functional heterogeneity of 
serotonergic neurons within the DRN (Sakai & Crochet, 2001).  
 
Later studies, performed on head-restrained rats (Urbain et al., 2006) and mice (Sakai, 2011) 
have revealed a similar heterogeneity of serotonergic neuronal firing across the sleep-wake 
cycle. It should be noted that no definitive proof of the serotonergic nature of these neurons 
was provided in any of these studies, therefore a portion of the neurons may in fact be non-
serotonergic. Future recordings from neurons in the DRN therefore require labeling to 
establish their serotonergic nature. However given these results it is very likely that atypical 
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serotonergic neurons have been underrepresented in electrophysiological studies because 
they do not conform to properties that were considered diagnostic of serotonergic neuronal 
identity i.e. highest discharge rate during wakefulness.  
 
1.4 Regulation of serotonergic neurons in the DRN 
 
5-HT neuronal activity in the DRN is controlled by two main mechanisms: autoregulation, 
arising directly from 5-HT neurons and heteroregulation, arising from local neurons and 
afferents including; GABAergic (Gervasoni et al., 2000), glutamatergic (Lee et al., 2003) and 
noradrenergic inputs (Peyron et al., 1996).  
 
1.4.1 Autoregulation of serotonergic neurons in the DRN 
 
5-HT neuronal activity and 5-HT release is controlled by 5-HT1A receptors located on the soma 
and dendrites of 5-HT neurons (Riad et al., 2000; Sotelo et al., 1990). Activation of local 5-HT1A 
autoreceptors by application of 5-HT1A agonists into the DRN reduces serotonergic cell firing in 
vitro (Aghajanian & Lakoski, 1984) and in vivo (Sprouse & Aghajanian, 1987; Fornal et al., 
1994). This decrease in neuronal firing occurs via 5-HT1A receptors, which are coupled to a G-
protein coupled inwardly-rectifiying potassium (GiRK) channel. Therefore, activation of 5-HT1A 
receptors causes an increase in K+ conductance that leads to a hyperpolarisation of 
serotonergic neuronal membranes (Katayama et al., 1997; Penington et al., 1993). 
Surprisingly, there is very little evidence to support that 5-HT1A autoreceptors are functionally 
active under physiological conditions. While some in vivo studies have demonstrated that the 
5-HT1A antagonist, WAY 100635 produces a disinhibitory effect on the firing of DRN 5-HT 
neurons (Fornal et al., 1996; Hajos et al., 2001), others have found little or no effect (Gartside 
et al., 1995; Haddjeri et al., 2004). A recent in vitro study has provided evidence that WAY 
100635 can also act at α1 adrenoreceptors located in the DRN, suggesting that at high 
concentrations the drug may mask endogenous 5-HT1A auto-inhibition (Liu et al., 2005). The 
response of 5-HT neurons to application of 5-HT1A agonists has been shown to vary across 
different subdivision of the DRN (Calizo et al., 2011). A recent genetic study has demonstrated 
that the magnitude of 5-HT neuronal autoinhibition is not related to the sensitivity of 5-HT1A 
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receptors, suggesting that adaptive changes in receptor sensitivity can occur to compensate 
for alterations in 5-HT levels (Araragi et al., 2013). These data have important clinical 
implications for the control of the sleep-wake cycle, pathogenesis of mood disorders and in 
the action of antidepressant drugs. 
 
Autoregulation of 5-HT neurons is also controlled in part by 5-HT1B receptors however reliable 
evidence for this regulatory role in the DRN is somewhat limited. 5-HT1B receptors have been 
shown to be located on the axon terminals of 5-HT neurons in the DRN (Boschert et al., 1994; 
Doucet et al., 1995; Riad et al., 2000) and their activation leads to a decrease in the release of 
5-HT (Adell et al., 2001; Morikawa et al., 2000). A recent study has revealed that activation 5-
HT1B receptors can enhance SERT activity in the DRN of mice (Hagan et al., 2012) supporting an 
autoregulatory role for these receptors. An autoregulatory role for 5-HT1D receptors in the 
DRN has also been suggested (Stamford et al., 2000) however the evidence for this is scarce 
due to the limited availability of selective ligands. The physiological relevance of multiple 5-HT1 
receptors regulating 5-HT neurons is currently unknown. Given the recent demonstration that 
not all 5-HT neurons express 5-HT1A receptors (Kiyasova et al., 2013), it is possible that 5-HT1B 
and 5-HT1D receptors could provide heterogeneous regulation of 5-HT neurons in the DRN. 
 
1.4.2 Heteroregulation of serotonergic neurons in the DRN 
 
Neurochemical and morphological studies have revealed that serotonergic neurons in the DRN 
form synaptic connections with local GABAergic interneurons (Fu et al., 2010; Gervasoni et al., 
2000; Gocho et al., 2013). Immunohistochemical studies have demonstrated that GABAergic 
interneurons are preferentially distributed in the DRVL subdivision of the DRN (Brown et al., 
2008; Shikanai et al., 2012). These local GABAergic interneurons can negatively regulate the 
activity of 5-HT neurons and 5-HT release in the DRN. In support of this, GABAA and GABAB 
receptors have been shown to be located on DRN 5-HT neurons (Gao et al., 1993; Serrats et 
al., 2003). Release of GABA from local interneurons would therefore cause the inhibition of 
nearby 5-HT neurons. Electrophysiological studies have revealed that activation of local 
GABAergic interneurons, via 5-HT2A/2C receptors, causes an increase of inhibitory synaptic 
events onto 5-HT neurons (Liu et al., 2000). Interestingly, some 5-HT neurons have been 
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shown to co-express GABA (or its synthetic enzyme, GAD), suggesting a possible co-release of 
5-HT and GABA from neurons (Belin et al., 1983; Fu et al., 2010; Shikanai et al., 2012). This 
would represent a novel mechanism which would regulate 5-HT neuronal firing via 
autoregulatory feedback inhibition. Complicating matters further, postsynaptic 5-HT1A 
receptors (Calizo et al., 2011) and 5-HT1B receptors (Lemos et al., 2006) have been shown to 
regulate GABAergic interneurons in the DRN. Activation of 5-HT1A or 5-HT1B receptors 
expressed by GABAergic interneurons would therefore cause the indirect disinhibition of 5-HT 
neurons in the DRN. The heteroregulation of GABAergic interneurons by 5-HT1B receptors 
would account for the observation that application of selective 5-HT1B agonists, leads to an 
increase in 5-HT neuronal firing (Adell et al., 2001; Evrard et al., 1999).  
 
GABAergic inputs from outside of the DRN have been shown to synapse directly with 5-HT 
neurons in the DRN (Soiza-Reilly et al., 2013; Wang et al., 1992). Retrograde tracing combined 
with immunohistochemistry has revealed that GABAergic afferents into the DRN arise from 
various brain regions including the VLPO, lateral hypothalamus, VTA and vlPAG (Gervasoni et 
al., 2000). Numerous pharmacological and electrophysiological studies have provided 
evidence that GABA has an inhibitory influence on serotonergic neurons in the DRN. An early 
investigation demonstrated that ionotophoretic application of GABA to the DRN of 
anaesthetised rats reduced the firing of neurons, an effect reversed by the GABA antagonist, 
picrotoxin (Gallager & Aghajanian, 1976). A later study revealed that application of the 
selective GABAA receptor agonist, THIP and GABAB receptor agonist, baclofen reduced the 
firing of presumed 5-HT neurons recorded from rat brain slices (Judge et al., 2004). The 
physiological significance of GABA-inhibition in the DRN is highlighted by reports that GABA 
mediates the reduction of serotonergic neuronal activity during NREM and REM sleep. In rats 
and cats, local administration of the GABA receptor antagonist, bicuculline into the DRN during 
NREM sleep increased the discharge of serotonergic neurons to the level observed during 
wakefulness (Gervasoni et al., 2000; Levine & Jacobs, 1992). Furthermore in rats, it was 
demonstrated that local infusion of bicuculline into the DRN during REM sleep increased the 
firing of serotonergic neurons to the level observed during wakefulness (Gervasoni et al., 
2000). In contrast to rats, bicuculline infusion in the DRN of cats did not increase serotonergic 
neuronal discharge during REM sleep (Levine & Jacobs, 1992). This result was confirmed and 
extended with the demonstration that during REM sleep cats, serotonergic neuronal activity is 
reduced by “disfacilitation” of noradrenergic and histaminergic neurons rather than by 
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GABAergic inhibition (Sakai & Crochet, 2000). It is possible that these conflicting observations 
reflect species differences.  
 
Glutamatergic inputs to the DRN originate from a number of nearby brainstem sites, several 
hypothalamic nuclei and the cerebral cortex (Lee et al., 2003). It has been demonstrated that 
the majority of glutamatergic terminals synapse on non-5-HT neurons in the DRN (Commons 
et al., 2005), recently confirmed to be GABAergic neurons (Soiza-Reilly et al., 2013). Glutamate 
has an excitatory effect on DRN 5-HT neurons which is mediated via both glutamate and 
AMPA/kainate receptors (Pan et al., 1989). Therefore while glutamatergic inputs can directly 
excite DRN 5-HT neurons, evidence exists to suggest that glutamatergic neurons could restrain 
5-HT neurons by feed-forward inhibition via GABAergic neurons.  
 
Early electrophysiological studies revealed that the number of spontaneously active 5-HT 
neurons was much lower when recording in vitro from acute brain slices in comparison to in 
vivo (Vandermaelen & Aghajanian, 1983). This observation suggested that spontaneous firing 
of 5-HT neurons in the DRN was dependent upon an intact excitatory afferent drive and 
subsequent studies revealed that noradrenergic input from the LC was the source (Baraban 
and Aghajanian, 1980; Baraban and Aghajanian, 1981). Pharmacological investigations have 
revealed that noradrenaline directly excites 5-HT neurons via postsynaptic α1-adrenoreceptors 
(Trulson & Crisp, 1984; Vandermaelen & Aghajanian, 1983) and indirectly inhibits 5-HT 
neurons via presynaptic α2-adrenoreceptors (Garratt et al., 1991). The release of 5-HT in the 
DRN is similarly regulated by α1- and α2-adrenoreceptors (Pudovkina et al., 2003). 
Noradrenergic neurons have a discharge profile similar to 5-HT neurons, firing fastest during 
wakefulness and slowing during sleep (Takahashi et al., 2010). Application of the selective α1 
adrenoreceptor agonist, phenylephrine to the DRN can block the cessation of discharge of 5-
HT neurons during REM sleep (Sakai & Crochet, 2000). Taken together these results 
demonstrate an important physiological role for the noradrenergic innervation of DRN 5-HT 
neurons during the sleep-wake cycle.  
 
 
24 
 
 
1.5 The role of serotonin in the sleep-wake cycle 
 
The role of serotonin in the sleep-wake cycle has evolved considerably over the last five 
decades. In the 1960’s a series of studies were performed in cats in order to investigate the 
role of raphe serotonergic neurons in sleep-wake control. Lesion studies revealed that there 
was a significant correlation between the destruction of the DRN and the decrease of both 
NREM sleep and cerebral levels of 5-HT (Jouvet, 1968 & 1969). Neuropharmacological studies 
revealed that the chemical destruction of serotonin by pCPA injection produced a dose-
dependent reduction in the amount of sleep (Koella et al., 1968).  Taken together these 
studies formed the basis for the “monoaminergic theory of sleep and waking” which 
postulated that 5-HT neurons in the DRN were responsible for NREM sleep (Jouvet, 1972). 
However, a serious challenge to the concept of 5-HT as a sleep transmitter came in the 1970’s 
with the development of techniques making it possible to record unit data in spontaneously 
sleeping cats. It was revealed that the unitary electrical activity of DRN neurons increased 
during waking then decreased during NREM sleep, becoming silent during REM sleep (McGinty 
& Harper, 1976). This pattern of DRN neuronal firing was later confirmed in rats (Guzmán-
Martin et al., 2000). The unit data was supported by microdialysis studies which confirmed 
that 5-HT release in several brain regions was highest during waking, reduced during NREM 
sleep and even more reduced during REM sleep in both cats (Portas & McCarley, 1994) and 
rats (Portas et al., 1998). These studies, as well as many others conducted during the 1980’s, 
led to the revision of 5-HT as a wake-promoting neurotransmitter. The appearance of new 
techniques and new data from the 1980’s onwards however did not simplify the role of 5-HT 
in wake control, rather it revealed the complex nature of 5-HT regulation and release of the 
sleep-wake cycle.  
 
 
1.5.1 Effects of 5-HT receptors on the sleep-wake cycle 
 
There have been various strategies aimed at understanding the role of 5-HT receptors in the 
regulation of the sleep-wake cycle including:  genetic (knock-out, KO) studies, intra-raphe 
delivery of 5-HT receptor ligands and systemic or intracerebroventricular (i.c.v) administration 
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of 5-HT receptor ligands. To date, investigations aimed at characterising the role of 5-HT 
receptors on the sleep-wake cycle have been limited to the 5-HT1A-1B, 5-HT2A-B-C, 5-HT3, 5-HT6 
and 5-HT7 (Monti et al., 2011). It should be noted that methodological differences between 
studies can produce inconsistencies in results and therefore care should be taken when 
interpreting the overall result. A brief summary of studies investigate the role of 5-HT1A and 5-
HT2A-2C receptors is discussed here.  
 
5-HT1A receptor regulation of REM sleep had been demonstrated previously in a number 
studies using a pharmacological approach. Microdialysis perfusion of the 5-HT1A agonist, 8-OH 
DPAT into the DRN was shown to increase REM sleep compared to perfusion with artificial 
cerebrospinal fluid (aCSF) in both cats (Portas et al., 1996) and rats (Bjorvatn et al., 1997), 
while wake and NREM sleep remained unaffected. In support of these finding, microinjection 
(i.e. direct infusion) of 8-OH-DPAT in the DRN increased REM sleep in rats, and this effect was 
inhibited by local infusion of the 5-HT1A antagonist, WAY100635 (Monti & Jantos, 2002). 
Microinjection of WAY100635 (Monti & Jantos, 2002) or a second antagonist, p-MPPI 
(Sørensen et al., 2001) into the DRN reduced REM sleep. 5-HT1A receptor knock-out mice (i.e. 
mice that do not express 5-HT1A receptors) have been observed to exhibit greater amounts of 
REM sleep than wild type (WT) mice, while wakefulness and NREM remain unaffected (Boutrel 
et al., 2002). From this study it was proposed that the increase in behavioural state in 5-HT1A 
receptor KO mice is due to the absence of postsynaptic 5-HT1A mediated inhibition of LDT/PPT 
REM-on neurons. In support of this, microinjection of 8-OH-DPAT or a second agonist, 
flesinoxan into the LDT selectively inhibited REM sleep in the cat (Stanford et al., 1994) and rat 
(Monti & Jantos, 2003). These data are therefore consistent with the hypothesis that 5-HT1A 
receptors in the LDT/PPT have an inhibitory role in REM sleep generation (McCarley et al., 
1995). Systemic application of 5-HT1A ligands has been reported to have quite different effects 
to local application. Therefore, systemic application of 8-OH-DPAT consistently increases 
waking while decreasing NREM and REM sleep in animals (Bjorvatn et al., 1997; Monti & 
Jantos, 1992; Monti & Jantos, 1994). There was however some evidence to suggest that 
different doses of 8-OH-DPAT have opposite effects on behavioural state i.e. at lower doses, 8-
OH-DPAT decreases waking (Monti & Jantos, 1992). It is not currently known what causes the 
observed increase in wake following systemic administration of 5-HT1A agonists, however, it is 
proposed that it may be due to inhibition of the sleep-promoting GABAergic neurons in the 
VLPO (Monti, 2010). 
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5-HT2A and 5-HT2C KO mice both show a significant increase of wakefulness and a reduction in 
NREM sleep while REM sleep remains unchanged (Frank et al., 2002; Popa et al., 2005). 
Interestingly, opposite effects have been demonstrated by pharmacological manipulation of 5-
HT2 receptors. Therefore, systemic administration of non-selective 5-HT2A/2C agonists or a 
selective 5-HT2C agonist has been demonstrated to increase wakefulness and decrease sleep 
(Monti, 2010).  The reason for this discrepancy is currently unclear however it has been 
suggested that the greater amount of wakefulness in 5-HT2C (and 5-HT2A) KO mice could be 
due to the increase of catecholaminergic neurotransmission involving the noradrenergic and 
dopaminergic systems (Frank et al., 2002). 5-HT2A and 5-HT2C receptors are expressed on 
GABAergic interneurons which participate in the control of noradrenergic and dopaminergic 
neurons (Fink et al., 2007). Hence, the reduction of GABA release at these sites in 5-HT2A and 
5-HT2C KO mice could be indirectly responsible for the increased levels of noradrenaline and 
dopamine (Monti, 2010). Infusion of the non-selective 5-HT2A/2C agonist, DOI into the DRN 
induced a significant reduction of REM sleep (Monti et al., 2006a). This reduction of REM sleep 
was prevented by pre-treatment with selective 5-HT2A and 5-HT2C antagonists (pruvanserin and 
EMD 281014, respectively). Systemic or intra-raphe administration of DOI consistently 
inhibited the firing of serotonergic neurons, an effect shown to be mediated via GABAergic 
interneurons (Liu et al., 2000). Therefore the observed DOI effect on REM sleep does not 
appear to be mediated directly via serotonergic neurons but rather by indirect activation of 
GABAergic interneurons. Similarly, in the LDT, 5-HT2A/2C receptor expression is absent from 
cholinergic neurons but is present in GABAergic interneurons (Fay & Kubin, 2001). In keeping 
with this, DOI has an indirect inhibitory effect on cholinergic neurons in the LDT which results 
in decreased REM sleep episodes (Amici et al., 2004). Systemic administration of 5-HT2 
antagonists has been consistently shown to increase NREM sleep in animals (Monti & Jantos, 
2006a, b; Monti et al., 2011; Morairty et al., 2008). Given the robust increase in NREM sleep of 
animals, numerous studies have been conducted in humans in order to investigate the 
therapeutic potential of 5-HT2 receptor antagonists as sleep aids. When given to healthy 
subjects, the non-selective 5-HT2 receptor antagonists, ritanserin and ketanserin have been 
shown to increase stage 3 and 4, and stage 2 of NREM sleep, respectively (Idzikowski et al., 
1986; Sharpley et al., 1994). In addition, the 5-HT2 inverse agonist, nelotanserin has been 
shown to increase NREM sleep and increase the duration of sleep bouts (Al-Shamma et al., 
2010). The precise mechanisms for this reliable increase in NREM sleep (observed in animals 
and humans) is currently unclear although it is reasonable to postulate that inhibition of cell 
groups involved in wake-promotion, either indirectly or directly, is likely.  
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1.6 Orexins (hypocretins) 
 
The neuropeptides orexin-A and orexin-B (hypocretin-1 and hypocretin-2) were concurrently 
and independently discovered as endogenous ligands in the brain (de Lecea et al., 1998; 
Sakurai et al., 1998). Orexin-A and orexin-B are comprised of 33 and 28 amino acids, 
respectively, with a 46% amino acid sequence homology. Both neuropeptides are produced 
from a common precursor polypeptide, prepro-orexin (prepro-hypocretin) which is expressed 
in the lateral hypothalamus and perifornical nucleus (Peyron et al., 1998a). Importantly, 
orexin-containing neurons project throughout the brain with particularly dense innervation of 
the ascending arousal system, including the LC, TMN and DRN (Nambu et al., 1999; Peyron et 
al., 1998a). Two orexin receptors have been discovered; orexin-type 1 receptor and orexin-
type 2 receptor (OX1R and OX2R). Orexin-A has equal affinity at both receptors whereas orexin-
B has a 10-fold greater affinity at the OX2R (Sakurai et al., 1998).  In situ hybridization has 
revealed that orexin receptors are distributed throughout the brain, each having a distinct, yet 
overlapping pattern (Marcus et al., 2001). Several studies have also demonstrated that in 
some brain regions, including the DRN, mRNA for both receptors can be co-localised (Eriksson 
et al., 2001; Brown et al., 2002). OX1 and OX2 receptors belong to the GPCR superfamily. 
Activation of orexin receptors by orexin-A or orexin-B predominantly produces a 
depolarisation in the postsynaptic cell leading to an increase in cell firing, hence orexins are 
universally considered to be excitatory neuropeptides (Brown et al., 2001; Eriksson et al., 
2001a, b). Studies have demonstrated that orexins produce their excitatory actions via Gq 
signaling although OX2Rs can also couple to Gs and Gi proteins (Hoang et al., 2003; Karteris et 
al., 2005). As described above, orexin neurons play an important role in promoting 
wakefulness via regulation of other ascending arousal pathways including the serotonergic 
neurons of the DRN.  
 
1.6.1 Regulation of DRN 5-HT neurons by orexins 
 
Immunohistochemical studies have demonstrated the orexin neurons innervate the DRN (Date 
et al., 1999; Nambu et al, 1999; Peyron et al., 1998a). A subsequent investigation using 
electron microscopy revealed that axon terminals of orexin neurons make synaptic 
connections with the dendrites and cell bodies of DRN neurons (Wang et al, 2003). A double-
labeling study later determined that orexin terminals were in fact synapsing with serotonergic 
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DRN neurons (Wang et al., 2005). Retrograde labeling has revealed that serotonergic neurons 
from the DRN also provide a reciprocal innervation of orexin neurons in the lateral 
hypothalamus (Yoshida et al., 2006). In situ hybridisation studies have shown that OX1 and OX2 
receptors are located in the DRN (Marcus et al., 2001; Trivedi et al., 1998). In the DRN, 
electron microscopy combined with staining has revealed that OX1Rs are expressed on both 
serotonergic neurons and non-serotonergic neurons in the DRN (Wang et al., 2005). The 
location of OX2Rs was not explored in this study therefore it remains to be elucidated whether 
OX2Rs are located on non-serotonergic neurons. Electrophysiological studies have revealed 
that application of orexin-A to DRN slices from the rat produced an excitation of 5-HT neuronal 
firing and a depolarization of the membrane voltage (Brown et al., 2001). A subsequent study 
compared the effects of orexin-A and orexin-B and given the affinity difference of the two 
ligands, suggested that the orexin-induced depolarisation was predominantly mediated by the 
OX2R (Brown et al., 2002). Furthermore in this study, current-voltage responses of 
serotonergic neurons to application of orexin-A were consistent with the involvement of a 
non-selective cationic channel. The authors hypothesised that the channel could be the 
canonical form of the transient receptor potential (TRP). In a parallel study, orexin-A and 
orexin-B also increased the firing of 5-HT neurons in the DRN (Liu et al., 2002). Interestingly, at 
higher concentrations the neuropeptides also increased discharge frequency of local 
GABAergic interneurons suggesting a possible feed-forward inhibition in the DRN. 
Complicating matters further, electrophysiological recordings have demonstrated that orexin-
B can depress glutamatergic input onto serotonergic neurons (Haj-Dahmane & Shen, 2005). 
Further investigation by these authors revealed that the depression of glutamatergic signaling 
was mediated via retrograde endocannabinoid release. Infusion of orexin-A and orexin-B into 
the DRN of freely moving rats has been shown to increase 5-HT release (Tao et al, 2006). Thus 
far no in vivo studies have been performed to elucidate the physiological role of orexin-
mediated regulation of GABA and glutamate neurons in the DRN.  
 
1.7 Histamine 
 
Histamine is an important monoamine with diverse functions in the body. In the brain, 
histamine is synthesised from the L-histidine through oxidative decarboxylation by histidine-
decarboxylase (HDC) (Fleming et al., 2004). The rate of histamine synthesis is determined by 
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the bioavailability of L-histidine, which can be transported into neurons by L-amino acid 
transporters (Haas et al., 2003). Histamine synthesis can be inhibited by exogenous application 
of α-fluromethylhistamine, an irreversible inhibitor of the HDC enzyme (Kollonitsch et al., 
1978). In neurons, histamine is carried into vesicles by the vesicular monoamine transporter 
(VMAT-2) and is released upon the arrival of action potentials (Merickel & Edwards, 1995). No 
high-affinity uptake system for histamine has been reported. Instead, inactivation of histamine 
in the extracellular space is achieved by methylation to tele-methylhistamine by neuronal 
histamine N-methyltransferase (HNMT) (Barnes & Hough, 2002). Histamine-producing 
neurons are located exclusively in the TMN of the posterior hypothalamus (Ericson et al., 
1987). The terminal areas of histaminergic projections from the TMN are widespread 
throughout the entire brain. The cerebral cortex, substantia nigra, amygdala and striatum 
receive dense histaminergic innervation while the hippocampus and thalamus receive more 
moderate staining (Lee et al., 2008; Panula et al., 1989). Reciprocal innervations between 
histaminergic TMN neurons and other aminergic cell groups including the DRN and LC have 
been reported (Lee et al., 2005a). GABAergic and galanergic neurons from the sleep-
promoting VLPO have also shown to input onto the cell bodies and proximal dendrites of 
histaminergic TMN neurons (Sherin et al., 1998).  
 
1.7.1 Histamine receptors 
 
There are currently known to be four histamine receptors (H1-H4) all of which belong to the 
rhodopsin-like family of GPCRs (Alexander et al., 2011). H1-H3 receptors are expressed robustly 
in the brain whereas the H4 receptor occurs mainly in the periphery (De Esch et al., 2005). In 
invertebrates histamine has been shown to activate ionotropic receptors (Hardie, 1989) and 
more recently two genes for histamine-gated ion channels have been discovered (Gisselmann 
et al., 2002). The molecular structure of a similar histamine-gated ion channel in vertebrates 
has remained elusive however histamine has been shown to directly open recombinant 
heteromultimeric GABAA receptors (Bianchi et al., 2011; Saras et al., 2008). 
 
H1Rs are expressed throughout the brain including the brainstem, hypothalamus, thalamus, 
cortex and hippocampus (Martinez-Mir et al., 1990; Palacios et al., 1981). Binding studies 
utilizing [3H]mepyramine suggest that a significant portion of H1Rs are associated with non-
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neuronal elements e.g. glia and blood vessels. Activation of H1Rs normally leads to neuronal 
excitation on postsynaptic cells in all of these areas (Brown et al., 2002; McCormick & 
Williamson, 1991; Selbach et al., 1997). Classical (first generation) antihistamines acts at H1 
receptors and have well-known sedative properties (Reiner & Kamondi, 1994; Unno et al., 
2012) although it should be noted that part of the sedation may have been due to non-specific 
anticholinergic activity. More recent (second generation) antihistmamines e.g. cetirizine and 
loratadine have less profound sedative properties in part due to more specific H1R binding and 
in part due although their reduced ability to cross the blood brain barrier. The signal 
transduction of H1Rs occurs via Gαq/11 coupling (Haas et al., 2008). Activation of PLC leads to 
the formation of diacylglycerol (DAG) and inositol triphosphate (IP3). IP3 releases Ca
2+ from 
intracellular stores leading to the activation of a number of Ca2+-dependent process 
throughout the brain including: activation of Na+/Ca2+ exchange in supraoptic neurons (Smith 
& Armstrong, 1996), opening of K+ channels resulting in hyperpolarisation of pyramidal cells in 
the hippocampus (Selbach et al., 1997) and cGMP formation in cultured mouse neuroblastoma 
cells (Richelson, 1978). DAG activation of PLC can cause excitation in the thalamus and 
hippocampus via closure of K+ channels (Brown & Haas, 1999; McCormack & Williamson, 
1991). Furthermore, activation of H1Rs on serotonergic neurons of the DRN leads to the 
activation of a mixed cationic conductance believed to belong to the transient receptor 
potential family (TRPC) (Brown et al., 2002; Sergeeva et al., 2003).  
 
H2Rs are also expressed throughout the brain and can be co-localised with H1Rs many brain 
regions e.g. DRN (Barbara et al., 2002), hippocampus (Garbarg & Schwartz, 1988) and cerebral 
cortex (McCormack & Williamson, 1989). A synergistic interaction of H1 and H2 receptors has 
been suggested after the observation of amplified histamine-induced stimulation of cAMP in 
hippocampal cells (Garbarg & Schwartz, 1988).  The H2R is coupled to Gαs and its signal 
transduction includes stimulation of adenylate cyclase and increase in intracellular cAMP 
which activates protein kinase A and the transcription factor CREB (Baudry et al., 1975; Haas et 
al., 2008). H3Rs re coupled to Gi/o proteins and high voltage activated Ca
2+ channels and are 
negatively coupled to cAMP. H3Rs function as autoreceptors on the soma, dendrites and axons 
of TMN neurons (Arrang et al., 1987; Pollard et al., 1993) causing inhibition of cell firing and 
histamine release (Stevens et al, 2001). In addition, H3Rs function as presynaptic 
heteroreceptors, to control the release of a variety of other transmitters including 
acetylcholine (Blandina et al., 1996) and noradrenaline (Schlicker et al., 1999). Distribution of 
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H3Rs is widespread throughout the brain, with expression normally present in areas known to 
receive histaminergic innervation (Chazot et al.,2001; Pillot et al., 2002). Transient expression 
of H1 receptors in SV40 cells (Bakker et al., 2000) and H2 receptors in CHO cells (Smit et al., 
1996) has revealed that these receptors are constitutively active in vitro. To date, only the H3 
receptor has been shown to be constitutively active in vivo (Morisset et al., 2000).   
 
1.7.2 Regulation of 5-HT DRN neurons by histamine 
 
Retorgrade studies have demonstrated that histaminergic neurons from the TMN innervate 
the entire rostro-caudal extent of the DRN (Lee et al., 2005a). Binding studies with [3H] 
mepyramine and [3H]-tiotidine have revealed that H1 and H2 receptors are located in the DRN 
(Bárbara et al., 2002). Furthermore, high levels of H3 receptor mRNA have been localised in the 
DRN (Drutel et al., 2001; Pillot et al, 2002). Early electrophysiological studies suggested that 
histamine reduces the firing of 5-HT neurons in the DRN via the H2 receptor (Lakoski & 
Aghajanian, 1983; Lakoski et al., 1984). Subsequent electrophysiological studies have shown 
that application of histamine to slices containing the DRN results in an increase in the firing of 
serotonergic neurons (Bárbara et al., 2002; Brown et al., 2002). The histamine-induced 
increase in 5-HT neuronal firing was shown to be mediated via the H1 receptor and not the H2 
receptor (Bárbara et al., 2002). Furthermore, the histamine induced excitation of 5-HT 
neurons appears to be mediated via non-selective cationic conductance, identical to that 
described from orexin receptors in the DRN (Brown et al., 2002). In support of this, occlusion 
experiments in the DRN have revealed that histamine, orexin and noradrenaline converge on a 
common ionic mechanism to increase the firing the serotonergic neurons (Brown et al., 2002).  
 
 
1.8 Aims 
 
This thesis aims to develop the understanding of how serotonergic neurons in the DRN are 
regulated by transmitters systems involved the sleep-wake cycle. In order to investigate this 
broad study aim the project was divided into three main sections. 
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1. How are mouse DRN serotonergic neurons regulated by 5-HT2 receptors, orexin receptors 
and adrenoreceptors in vitro? It was hypothesised that activation of 5-HT2 receptors in the 
nucleus would produce inhibition of 5-HT neurons while activation of orexin and 
adrenoreceptors would produce excitation. Extraceullar and patch clamp electrophysiology 
was utilised and combined with pharmacological investigation of serotonin neurons in mouse 
brain slices.  
 
2. How are DRN serotonergic neurons regulated by histamine receptors in vitro? It was 
hypothesised that activation of H1 and H2 receptors would cause an excitation of 5-HT neurons 
while activation of H3receptors would cause an inhibition. Similar to the previous aim patch 
clamp electrophysiology was utilised in order to investigate the histaminergic regulation of 5-
HT neurons in mouse brain slices. 
 
3. How are DRN serotonergic neurons regulated by histamine receptors in vivo? It was 
hypothesised that blockade of histamine receptors in the DRN would lead to reduced level of 
firing of 5-HT neurons and more widely a profound sedation of the whole animal. Extraceullar 
recordings, and separately, EEG recordings were performed in rats in order to investigate the 
pharmacological inhibition of H1Rs. 
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Chapter 2: 
Materials and Methods
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2.1 Animal supply, housing and breeding 
 
All animal procedures were carried out in accordance with UK home office guidelines laid out 
in the U.K Government Animals (Scientific Procedures) Act 1986. Furthermore all procedures 
were performed in accordance with the University of Dundee and Eli Lilly code of practise for 
use of experimental animals. Every effort was taken to reduce animals use and suffering. 
 
In vitro slice experiments were carried out on neonatal (P16-P30), wild-type (WT), C57/BL6 
mice of either sex which were obtained from an in-house colony maintained within the 
Medical School Resource Unit at the University of Dundee. Animals were kept under 
controlled conditions with a 12 hour light: 12 hour dark cycle, constant temperature (21 ± 2°C) 
and humidity (55%) and provided with food and water ad libitum. Animals were killed by 
cervical dislocation in accordance with Schedule 1 of the Animals (Scientific Procedures) Act 
1986 (Maguire et al., 2013). In vivo experiments were carried out on adult (250-370g), male, 
Wistar rats which were obtained from Charles River laboratories (Wilmington, MA, USA) and 
housed within the animal research facility at Eli Lilly. Animals were kept under controlled 
conditions with a 12 hour light: 12 hour dark cycle, constant temperature (21 ± 2°C) and 
humidity (55%) and provided with food and water ad libitum. After completion of in vivo 
experiments rats were terminally anaesthetised (Rasmussen et al., 2004). 
 
2.2 Electrophysiological recording from brain slices 
 
Understanding the relationship between the electrical activity of individual neurons and the 
behaviour they mediate is major goal in the field of neuroscience. In neurons, the generation 
of action potentials reflects the combination of intrinsic membrane properties and extrinsic 
inputs from neurotransmitters. The in vitro brain slice preparation offers a direct approach to 
investigate the changes in electrical characteristics that govern neuronal behaviour. Numerous 
studies have demonstrated comparable electrical activity between brain slices and the intact 
animal thereby solidifying the importance of the brain slice preparation in neurophysiology 
research. Extracellular single-unit recordings and whole-cell voltage-clamp recordings have 
been combined here in order to study the electrophysiology of neurons within the DRN. 
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Extracellular recordings are performed in order to obtain information about the electrical 
activity of single neurons (single-unit recordings). Extracellular recordings are useful for 
studying the firing properties of neurons and have the advantage of producing very stable and 
long-lasting experiments. However single-unit recordings can only provide limited 
electrophysiological information about individual neurons. In order to better understand the 
intrinsic cellular properties that govern the electrical behaviour of neurons more advance 
techniques are required. Whole-cell patch-clamp recordings allow high resolution recordings 
to be made from individual neurons and permit a more detailed understanding of their cellular 
properties. In particular, voltage-clamp recordings allow the study of ionic conductance across 
cellular membranes.  
 
2.3 Slice preparation  
 
Following cervical dislocation and decapitation the brain was rapidly removed and placed in 
ice cold (0-4°C) oxygenated (95% O2, 5%CO2) artificial cerebrospinal fluid (aCSF) containing (in 
mM): 126 NaCl, 26 NaHCO3, 10 MgSO4, 10 Glucose, 2.5 KCl, 1.25 NaH2PO4, 0.5 CaCl2, (pH 7.4, 
309-312mOsm). A small section of the frontal lobe was removed to form a flat base and to 
allow coronal sections to be taken in the caudal to rostral direction. The brain was dried on 
filter paper and then mounted on the metal base of a vibratome plate using cyanoacrylate 
(Super) glue. It was then submerged in oxygenated, ice-cold aCSF in the slicing chamber. 
Coronal slices were cut (thickness 300-350µM) using a Vibratome series 1000 (Intracel; 
Royston, Hertfordshire, UK) and then transferred to a holding chamber containing circulating, 
oxygenated aCSF at room temperature. Slices were placed on a suspended nylon mesh 
platform, allowed to recover for 1 hour and used for experimentation between 1 and 8 hours 
after slicing. Generally 3-4 good quality slices containing the DRN were obtained per animal.  
 
2.4 Reagents and drugs: in vitro electrophysiology 
 
All chemicals are listed in Table 1.1 with the corresponding site of action, concentration used, 
vehicle solution and the company from which they were obtained. Briefly, stock solutions of 
drugs were dissolved in destilled/de-ionised water or DMSO and final dilutions (x1000) were 
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made in extracellular recording solution, ECS (see section 2.5). DMSO was used to dissolve 
water-insoluble drugs and was always made as a concentrated stock to ensure the maximum 
DMSO concentration never exceeded 0.1%. This concentration had no effect upon ionic 
currents (data not shown). All drugs and salts were purchased from VWR (West Sussex, UK), 
Tocris (Bristol, UK), Sigma Aldrich (Dorset, UK), Abcam (Cambridge, UK) or were a kind 
donation from Eli Lilly (Surrey, UK). The osmolarity of solutions were measured using a 
Roebling Osmometer (Camlab, Cambridge, UK).  
 
For extracellular single-unit recordings drug application and solution perfusion was achieved 
by a pump fed perfusion system with a flow rate of 1-2 ml/min. All solutions reached slices 
within 3mins and were run to waste. Solutions were preheated before entering the recording 
chamber (block heater; Jencons, UK) and heated in-line (G23, University College London). This 
heating procedure was implemented to prevent the formation of bubbles which could perturb 
the recording. A heating element located in the lower chamber body ensured the temperate 
was maintained at 35 ± 0.5°C (PTC03; Digitimer, UK). For whole-cell patch-clamp recordings 
solution delivery was achieved by a gravity-fed perfusion system with a flow rate of 3-4 
ml/min. Solutions reached slices within 3 minutes and were recycled with a peristaltic pump 
(Gilson, UK). A metal probe was placed within the chamber in close proximity to the slice and 
the temperature was maintained at 35 ± 0.5 °C by a temperature controller (School of 
Pharmacy, University of London). In certain experiments drugs were focally applied to neurons 
via a drug-filled pipette which was placed in close proximity to the neuron (within 1000μm). 
The glass pipette was made from the same capillary tubing as the patching electrode but had a 
lower resistance of 1-2 MΩ. The pipette was placed in an MP Series microinjection electrode 
holder and positioned close to the neurone using an MX10 micromanipulator (Stratton 
Technologies, Bedfordshire, UK). Ejection of the drug from the pipette was achieved using a 
pneumatic system operated by a Picosprtizer II unit (Intracel, Hertfordshire, UK).  The pressure 
and duration of the drug delivery was adjusted according to the position of the pipette in 
relation to the cell. The drug was normally diluted by a factor between 10 and 30 when it 
reached the neuron (estimated by comparison with bath applications of known concentrations 
of the drug). Focal drug application could be delivered manually or via an automated system 
using an external stimulator (Grass S88 Stimulator, West Warwick, USA). The frequency and 
duration of drug application was kept constant throughout each experiment. 
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2.5 Extracellular single-unit recordings 
 
Slices (350µM thick) were transferred to an interface recording chamber (BSC1 chamber; 
Digitimer, UK) where they were perfused with oxygenated extracellular recording solution 
(ECS) containing (in mM): 126 NaCl, 26 NaHCO3, 10 glucose, 2.95 KCl, 2 MgCl2, 2 CaCl2 and 1.25 
NaH2PO4 (306-309mOsm). The ECS was delivered at a rate of 1-2 ml/min and maintained at 
35°C. The DRN was visualised with a dissecting microscope (Olympus SZ30, UK) equipped with 
a x10 objective lens. Glass microelectrodes were prepared from glass capillary tubing   
(0.95mm I.D., 1.55mm E.D., Garner Glass Co., Claremont, CA) using a PP830 electrode puller 
(Narashige, Japan) to have a resistance of 1-3MΩ when filled with 2M NaCl. Filled electrodes 
were positioned above the DRN using a micromanipulator (Warner Instruments, CT, USA) and 
then slowly advanced through the slice. Signals were recorded with a DP-301 differential 
amplifier (Warner Instruments, CT, USA) and fed to a PC via a 1401 computer analogue to 
digital converter interface (CED, UK) at a sampling rate of 100 Hz. Signals were filtered (500Hz-
3kHz) and when required, 50/60kHz noise was removed using a Humbug noise eliminator 
(AutoMate Scientific, USA). Data were collected using Spike2 software (version 5, CED, UK). 
The frequency of cell firing was monitored on line using a simple threshold crossing. 
 
2.5.1 Identification of putative 5-HT neurons in the DRN 
 
Putative 5-HT neurons were identified on the basis of their location: along the midline of the 
DRN (Abrams et al., 2004) and basal electrophysiological characteristics: regular spikes, 2-4ms 
duration with a slow frequency of 0.3-4.5Hz (Aghajanian & Vandermaelen, 1982b, Allers & 
Sharp, 2003). In coronal sections the DRN was positioned ventral to the aqueduct, dorsal to 
the medial longitudinal fasciculus and superior cerebellar peduncle decussation and contained 
within the periaqueductal grey (Fig 2.1). Spontaneous (basal) firing can be recorded from DRN 
5-HT neurons however due to the removal of noradrenergic inputs to the nucleus during the 
slicing process many neurons do not display their characteristic basal firing. The α1-
adrenoreceptor agonist, phenylephrine (10μM) can be bath applied to the slice in order to 
increase the likelihood of 5-HT neuronal firing. In approximately 50% of neurons 10μM 
phenylephrine was used to drive firing. The addition of phenylephrine is highlighted in the 
relevant section. 
39 
 
 
 
2.5.2 Data analysis  
 
All data were analysed offline using Spike 2 software (Version 5, CED, UK). Events which were 
captured on-line were carefully checked and any noise was removed. This edited channel was 
then used to calculate the firing frequency and inter-event-interval (IEI). The spike width was 
calculated by averaging spikes over a 100s period from the raw trace. The basal firing rate 
(control) was determined in a 300s period at the start of each recording and expressed as an 
average frequency (Hz). Each response to drug was determined in a 300s period during the 
maximum change in the baseline and expressed as an average frequency (Fig 2.2). The drug 
response was then calculated as the percentage change relative to control (i.e. control = 100%, 
drug effect = % of control). The Coefficient of Variation (CV) was calculated (standard deviation 
divided by the mean inter-spike interval) for control and drug periods in order to measure 
spike train regularity. The reversibility of all drugs used was tested (data not shown).  
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Fig 2.1. Schematic illustration of the mouse brain on a sagittal and coronal plane illustrating 
the location of the DRN within the brainstem and the DRN subdivisions respectively. (A) Mid 
sagittal section of the mouse brain showing the DRN within the brainstem. The vertical line 
represents the level of coronal sectioning. (B) Coronal section of the brain (4.6mm posterior to 
bregma) with the DRN subdivisions outlined. The DRN lies ventral to the Aq and dorsal to the 
xscp. Abbreviations: Aq, aqueduct, DRD, dorsal raphe nucleus, dorsal part, DRV, dorsal raphe 
nucleus, ventral part, DRL, dorsal raphe nucleus, lateral part, DRI, dorsal raphe nucleus, 
interfascicular part, VLPAG, ventrolateral periaqueductal gray, mlf, medial longitudinal 
fasciculus, xscp, decussion of the superior cerebellar peduncle, MnR, median raphe nucleus 
(adapted from the Franklin & Paxinos mouse brain atlas, 2007). 
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Fig 2.2. Putative 5-HT neurones of the DRN fire spontaneously.  Representative extracellular 
recording trace (20min) from a spontaneously firing DR, 5-HT neuron. Action potentials 
(spikes) appear as sharp deflections from the baseline. Drug application is denoted by the 
horizontal line above the trace and is shown to start as soon as the drug solution begins to 
perfuse. The drug solution takes approximately 2mins to reach the slice (*). The average firing 
frequency for control is calculated from 5mins before drug application and the average firing 
frequency for drug is calculated from 5mins during its peak effect (dashed boxes). The 
reversibility of drug was also tested (data not shown).  
 
 
 
 
 
 
Drug application 
Control (5 min) Drug (5 min)
50s
*
10μM histamine 
42 
 
 
 
2.6 Patch-clamp electrophysiological recordings 
 
Slices (300µM thick) were transferred to submerged recording chamber and perfused with 
oxygenated ECS (as above). The ECS was delivered at a rate of 3-4 ml/min and maintained at 
35°C. Neurons within the DRN were visually identified using a black and white camera (Hitachi, 
CCD KP-MIE/K-510, USA) connected to an upright microscope (Zeiss Axioskop 2 FS, Zeiss, 
Welwyn Garden City, U.K.) equipped with Achromat x10 and x40 water-immersion optics. A 
further x1.6 magnification was achieved using an Optivar. Microscope images were displayed 
on a black and white video monitor (PVM-14SE, Sony, Korea). Recordings were obtained using 
an Axopatch 200B amplifier (Molecular Devices Ltd, CA, USA) connected to a CV-4 head stage. 
A set voltage command (-4mV, 30ms duration, every 0.1s) was supplied by an external, 
computer-based protocol stimulator (generated by WinEDR in the seal test mode) in order to 
monitor the formation of the whole-cell configuration and adjust whole-cell capacitance and 
series resistance values. All recordings and cell parameter adjustments were performed using 
a filter setting of 5kHz and a 8-pole low pass Bessel filter.  The filter bandwidth was reduced to 
2kHz for recording whole-cell currents.  
 
The recording electrode was positioned onto the selected neuron by using a PCS-5000 
piezoelectric micromanipulator (EXFO-Burleigh, Ontario, Canada). The electrode was advanced 
into the bath at which point corrections were made for offsets due to the liquid-junction 
potential (potential difference formed due to differences in the ionic concentration and 
mobilities between in the ECS and intracellular solution). Upon reaching the surface of the 
neuron the positive pressure was released and gentle negative pressure was supplied in order 
to form a tight (giga-ohm) seal with the cell membrane. A giga-ohm seal was confirmed by a 
stable, minimal holding current, near 0pA, at a holding potential of -60mV. Transient currents 
due to pipette capacitance were cancelled. Brief, sharp negative pressure was then applied to 
rupture the cell membrane and provide electrical access to the cell (whole-cell mode). The 
appearance of transient currents of opposite polarity confirmed the correct establishment of 
the whole-cell configuration (Fig 2.3). These transient currents emerged and decayed with the 
rising and falling edges of the step command and represented the charging and discharging of 
the membrane capacitance. The fast component of the transient current was minimised using 
whole cell capacitance and series resistance compensation in order to prevent saturation of 
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output from the head stage. A period of 3-5 minutes was allowed to elapse immediately after 
the whole-cell configuration was established in order to allow the dialysis of solutions 
between the electrode and cytosol. The access resistance was monitored throughout each 
experiment; the series resistance was 5-20 MΩ with up to 70% compensation (20μs lag). Cells 
were discarded if the series resistance exceeded 20 MΩ or changed significantly (20% 
tolerance) during the course of the recording.  
 
2.6.1 Whole-cell voltage-clamp recordings 
 
In the whole-cell voltage-clamp configuration currents were recorded at 35°C in ECS (as above) 
at a VHOLD of -60mV. Glycine receptors were blocked by the addition of 0.5µM strychnine to the 
ECS (as described previously by McGuire et al., 2013). Recording electrodes were prepared 
from glass capillary tubing to have a resistance of 3-6 MΩ when filled with intracellular 
solution (ICS). Electrodes were filled with CsCl- or KGluconate-based intracellular solutions. 
CsCl based intracellular contained (in mM): 140 CsCl, 10 HEPES, 10 EGTA, 2 MgCl2, 1 CaCl2, 2 
Mg-ATP and 5 QX-314 (pH 7.2 - 7.3, 314-319mOsm). This intracellular solution provides an 
equal intra- and extra-cellular chloride concentration thereby enabling the detection of 
GABAergic synaptic events (reversal potential ~ 0mV). The CsCl and QX-314 in the ICS blocked 
K+ conductances and leak Na+ currents respectively. KGluconate based intracellular contained 
(in mM): 130 K-gluconate, 10 HEPES, 0.2 EGTA, 2 KCl, 2 NaCl, 2 Mg-ATP, 0.5 GTP-Na, 10 
phosphocreatine-tris (pH 7.2 - 7.3, 285-295mOsm). This low chloride intracellular solution 
represents a near physiological ionic state allowing the detection of glutamatergic synaptic 
events (reversal potential ~0mV). Where stated, GTP was substituted for 1mM GDP-βS in the 
intracellular solution in order to inhibit G protein receptor signalling and 0.5µM TTX was 
included in the ECS in order to block Na+-dependent action potentials. Different ICS was used 
due to the observation that histamine-induced currents were difficult to record with CsCl ICS 
(possibly due to the blockage of K+ channels) therefore all recordings performed in Chapter 4 
utilised KGluconate ICS. 
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2.6.2 Cell-attached voltage-clamp recordings 
 
Cell-attached voltage-clamp recordings were made using the same equipment set up as 
described above, at 35°C in ECS. Electrodes were filled with ECS. Action currents were 
recorded from putative 5-HT neurons by lowering the electrode onto the cell, while applying 
positive pressure. Once contact was made with the cell gentle suction was applied to form a 
loose seal (< giga-ohm) with the membrane. Action currents were recorded at a voltage clamp 
that maintained a 0pA leak current (Perkins, 2006). The patch seal was regularly checked 
throughout the recording to ensure the seal was maintained and the cell did not enter whole-
cell configuration. 
 
2.6.3 Whole-cell current-clamp recordings 
 
Whole cell current clamp recordings were made at 30°C. The whole-cell configuration was 
achieved as described previously for whole-cell voltage-clamp experiments. Whole-cell 
capacitance and series resistance were estimated in the voltage-clamp mode and then 
recordings were switched to current clamp mode and bridge balance adjusted (using the 
series resistance control) to correct any voltage drop error. To monitor access resistance, 
recordings were regularly switched back to voltage clamp mode. Patch electrodes were filled 
with KGluconate solution (described above) and the osmolarity of the intracellular solution 
was increased to 310-320mOsm 1-1 with D-mannitol. The liquid junction potential was not 
corrected for. 
 
2.6.4 Identification of putative 5-HT neurons  
 
Putative 5-HT neurons were identified on the basis of their location and morphology. Neurons 
were densely populated along the midline and more sparsely populated in the lateral wings of 
the DRN. The neurons were larger when compared to local GABAergic neurons and displayed a 
varied morphology including round, fusiform, bipolar and multipolar neurons. Extensive 
immunohistochemistry carried out within the laboratory in partnership with an external 
collaborator has confirmed that these characteristics are hallmarks of 5-HT neurons (McGuire 
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et al., 2013).  
 
2.6.5 Data analysis 
 
Recordings were digitised using an analogue to digital converter (NI-DAQ mx; National 
Instruments, UK) at a 10 kHz sample rate onto a personal computer using the Strathclyde 
Electrophysiology Software (Electrophysiology Data Recorder (WinEDR) and Whole Cell 
Analysis Program (WinWCP); courtesy of Dr J. Dempster, University of Strathclyde, UK).   
 
IPSC 
Individual inhibitory postsynaptic potentials (IPSCs) were detected using an amplitude 
threshold algorithm (amplitude greater than -4pA, duration longer than 3ms) in WinEDR. 
Captured events were visually inspected for validity and were rejected if they contained 
multiple events, an unstable pre- or post-event baseline, or spurious noise. Individual IPSCs 
were analysed in WinWCP with respect to their peak amplitude, rise time, T50 (time to decay 
to 50%), T90 (time to decay to 90%) while a weighted decay time constant, w (Fig 2.4.A) was 
determined for the averaged signal (see below). Events with a rise time >1ms were removed in 
order to minimise the contribution of unquantifiable electrical filtering from dendritic IPSPs. 
Accepted events (a minimum of 40) were subsequently averaged by alignment with the mid-
point of the rising phase and fitted with either a mono- (Y(t)=Ae(-t/) or bi-exponential 
(Y(t)=A1e
(-t/) + A2e
(-t/)) decay function where Y(t) is the current amplitude at any given time t, 
A is the current amplitude at time zero and  is the decay time constant (Fig 2.4.B).  An F test 
was then used to determine whether the decay was best described by a mono- or bi-
exponential fit (indicated by a decrease in the standard deviation of the residuals). As the 
majority of IPSCs were best described by a bi-exponential decay, a weighted decay constant 
(w) was also calculated to describe the relevant contribution of each decay component 
according to the equation w = 1P1+2P2, where 1 and 2 are the decay time constants of the 
first and second exponential functions and P1 and P2 are the proportions of the current 
described by the respective components. 
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The frequency of IPSCs were analysed using WinEDR. Individual events were detected on the 
basis of their rate of rise (≤ 40 pA/ms). Recordings were then visually inspected to ensure all 
events were included and any detected spurious noise was removed. A 2 minute period was 
sufficient to calculate the frequency of events, grouped into six bins of 20 s. A mean frequency 
and inter-event interval was calculated from the average of the 6 bins. 
 
Tonic and drug evoked currents  
Drug-induced currents indicative of changes in channel activity were quantified by calculating 
the difference between the holding current before and after drug application to the bath. The 
holding current and the root mean square (RMS i.e. standard deviation) were sampled every 
102.4ms over a 1min period for each experimental condition. At a sampling rate of 10kHz, 
1024 baseline points for each 102.4ms provided one data point. Epochs containing synaptic 
events, or an unstable baseline were excluded from the analysis. In order to ensure that any 
drug-induced change of the holding current was a genuine effect and not due to a temporal 
‘drift’, two 1min sections of the holding current during control were analysed (C1 and C2). 
Similarly, a 1min section was analysed following drug application, after the drug effect had 
reached plateau (D). Both the control sections (C1 and C2) and D were sampled at comparable 
temporal intervals to control for any temporal drift that may have occurred during the control 
section and following the drug application (Fig 2.5). The mean D.C. values for C1 and C2 were 
pooled and the standard deviation calculated. An effect of drug was considered genuine if the 
absolute value of change in the holding current following drug application (i.e. D – C2) was 
greater than twice the standard deviation association with the control section measurements.   
 
Cell firing 
In cell-attached voltage-clamp experiments investigating the effect of bath application of drug 
on action current frequency, events were automatically detected using WinEDR on the basis of 
their rate of rise (~ 40-120 pA/ms). The entire record was visually inspected to ensure that no 
action currents had been missed by the automated detection and to remove spurious noise 
that met the detection criteria. The IEIs were measured in control conditions and following 
bath application of drug onto the neurone and compared (Fig.2.6).  
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Focal drug application 
The change in holding current following focal (spritz) drug application was calculated using 
WinEDR. Focal drug responses had a slow onset and prolonged decay back to baseline 
(typically lasting 20-40s). Therefore the picrospritz channel was used to detect each focal 
application event and a 60s window was extracted to be analysed. The holding current and the 
RMS were sampled every 102.4ms over a 5s period for control and 2.5s period for the 
maximum drug effect (Fig. 2.7). As above, at a sampling rate of 10kHz, 1024 baseline points for 
each 102.4ms provided one data point. Epochs containing synaptic events, or an unstable 
baseline were excluded from the analysis. An averaged value for the change in holding current 
and RMS was obtained from 5 drug events during control (i.e. ECS perfusion) and during drug 
application (i.e. addition to the ECS). 
 
Input-output  
To estimate the impact of the histaminergic conductance upon the excitability of DR neurones, 
input-output curves estimating the number of action potentials (APs) fired in response to 
current injection were constructed. Input-output curves were calculated in current clamp 
mode by running a stimulus protocol that injected current pulses that increased sequentially 
from -40pA to +120pA in 20pA steps with a 400ms duration and a 15s delay between pulses. 
Each stimulus was repeated three times in the absence and presence of drug. Current 
injections were detected in WinEDR on the basis of their rate of rise and traces were inspected 
manually to remove spurious noise that falsely met the detection criteria. Action potentials 
were then manually detected within the pulse and the frequency calculated. 
 
Input resistance  
The input resistance was recorded in voltage-clamp mode by injecting a set voltage pulse (-4 
mV amplitude, 30 ms duration, 0.1 s interval). Two 10 s control periods (C1 and C2) were 
analysed to measure the current induced as a result of the voltage step with the input 
resistance being calculated from Ohm’s law (R = V/I). Similar to above, the control periods 
were compared to check for any temporal drift that may have occurred and then compared 
against the corresponding drug period (D – C2). The voltage pulses were detected using 
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WinEDR on the basis of their rate of rise. They were inspected to remove spurious noise that 
met the detection criteria and subsequently exported to WinWCP where the associated 
current changes were measured. Recordings were discarded and not analysed if following 
voltage injection a steady plateau was not reached. 
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Fig 2.3. Whole-cell recording configuration with corresponding RC circuit and current-voltage 
traces. (A) Left: A schematic representation of whole-cell recording configuration with the 
electrode patched on to a small area of the cell membrane. Right: The corresponding RC circuit 
showing the series resistance, Rs (Rpipette + Raccess) caused by the introduction of the pipette to 
the cell membrane which has resistance Rm and capacitance Cm. (B) A typical whole-cell 
current response to a set command voltage, Vc. Note that the current response is made up of 
a transient response formed by Rs and Cm and a steady-state component determined by Rm 
(adapted from Patch Clamping by Areles Molleman, 2003).   
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Figure 2.4. Representative whole-cell recording and associated analysis of IPSC from a DR 5-
HT neuron. (A) A representative whole-cell recording trace (15s) of IPSCs from a putative 5-HT 
neuron in the DRN voltage-clamped at -60 mV. (B) The peak amplitude, rise time, T50 and T90 
were calculated in WinWCP (C) Ensemble averaged IPSC with a superimposed  mono- (left) or 
bi- exponential (right) fit (blue). Note that the bi exponential decay provide a better fit  The 
frequency was calculated from the raw trace using WinEDR . See section X.Y for details of IPSC 
analysis, assessment of the best fit and frequency analysis). 
 
51 
 
 
 
0 200 400 600
-200
0
50s
25pA
Drug application
Control 2
Drug
Control 1
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5 Analysis of drug-evoked currents. A representative whole-cell recording from a 
presumed 5-HT voltage clamped at -60 mV before and after the bath application of Drug X. 
The holding current and RMS were calculated over two separate one minute periods during 
control (dashed boxes. control 1 and control 2). The holding current and RMS was calculated 
over one minute period during the maximal drug effect (dashed box, drug). 
 
 
 
 
 
10μM histamine 
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Figure 2.6 Analysis of cell-attached cell firing. A representative cell-attached recording from a 
presumed 5-HT neuron maintained at 0pA. The firing frequency and inter-event interval was 
calculated over 60s for control (dashed box) and drug (dashed box). 
10μM histamine 
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Figure 2.7 Analysis of focal drug application. (A) A representative whole-cell voltage-clamp 
(VH = -60mV) recording illustrating the holding current during focal (spritz) application of drug. 
(B) Expanded view of a single drug response. The holding current and RMS are calculated over 
a 5s period immediately prior to the drug application (dashed box, control). The holding 
current and RMS are then calculated during 2.5s of the maximal drug effect (dashed box, 
drug). 
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2.7 In vivo single-unit recordings 
 
Adult, male Wistar rats (280-370g) were anesthetised with 25% urethane administered via 
intraperotineal (i.p.) injection. An initial injection of 5ml/kg urethane was given followed by 
additional injections of 0.3ml (given at 20 minute intervals) until no foot and eye reflexes could 
be detected. The animal was then transferred to a heat pad and maintained at 37°C via a 
rectal probe attached to a homeothermic control unit (Harvard Apparatus, UK). The head was 
shaved and the animal was placed into a stereotaxic frame, secured by ear and teeth bars 
(KOPF Instruments, CA, USA). The tail vein was cannulated (24GA, 0.75”; Angiocath, UK) and 
secured in place with surgical tape to allow delivery of drugs. A midline incision was made over 
the skull and the subcutaneous tissues were cleared. The skull was visualised with a Zeiss 
microscope (OPMI pico) equipped with x1.6 magnification and adjusted to sit in the flat 
position (Fig.2.8). A 5mm2 hole was drilled 7.3mm posterior to Bregma and the exposed dura 
matter was cut. A miniature stainless steel screw was driven into the skull above the 
cerebellum and served as a ground electrode. A carbon fibre electrode with 0.4-1.2MΩ 
impedance (Carbostar-1; Kation Scientific, MN, USA) was position 7.5mm posterior from 
Bregma and 1.5mm lateral from the midline and set at an angle of 15° (Fig.2.9). The electrode 
was advanced to a depth of 5-6mm below the brain surface using a micromanipulator (IVM; 
Scientifica, UK). Signals were recorded with a NL104A pre-amplifier connected to a NL100AK 
headstage (Neurolog System, Digitimer, UK). Signals were filtered (500Hz-5kHz) and 50/60kHz 
noise was removed using a Humbug noise eliminator (AutoMate Scientific, USA). Signals were 
fed to a PC via a micro1401 analogue to digital converter interface (CED, UK) at a sampling rate 
of 32,000Hz. Data were collected using Spike2 software (version 5, CED, UK). The frequency of 
cell firing was monitored on line using a simple threshold crossing. Signals were only 
considered to be from serotonergic neurons if they displayed strict electrophysiological 
criteria: regular firing, 2-4ms spike duration with a slow frequency of 0.3-4.5Hz (Aghajanian & 
Vandermaelen, 1982b, Allers & Sharp, 2003).  
 
2.7.1 Data analysis 
 
All data were analysed offline using Spike 2 software (Version 5, CED, UK). Events which were 
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captured on-line were carefully checked and any noise was removed. This edited channel was 
then used to calculate the firing frequency and inter-event-interval (IEI). The spike width was 
calculated by averaging 100 spikes from the raw trace. The basal firing rate was determine in a 
10 minute period at the start of each recording and expressed as average frequency (Hz). All 
cells were then challenged with a vehicle treatment and a 10 minute section of recording was 
compared with the basal firing to assess if there was any effect. Each response to drug was 
determine in a 10 minute period during the maximum change in the baseline and expressed as 
an average frequency. The drug response was then calculated as the percentage change 
relative to vehicle (i.e. vehicle = 100%, drug effect = % of vehicle).  The Coefficient of Variation 
(CV) was calculated (standard deviation divided by the mean inter-spike interval) for control 
and drug periods in order to measure spike train regularity 
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Figure 2.8. Rat skull diagram. Dorsal and lateral views of the skull of a 290g Wistar rat. The 
positions of bregma, lambda and the plane of the interaural line are shown. Lambda is 0.3mm 
anterior to the coronal plain passing through the interaural line (adapted from Paxinos & 
Watson rat brain atlas 2005).  
 
 
 
 
 
 
 
 
Figure 2.9. Schematic of the rat brain on the coronal plain illustrating the DRN. Coronal 
section of the rat brain (-7.56mm from bregma). Electrode placement 1.5mm mediolateral at 
15° produces the electrode tract illustrated. VLPAG, ventrolateral periaqueductal gray, mlf, 
medial longitudinal fasciculus, xscp, decussion of the superior cerebellar peduncle, MR, 
median raphe nucleus (adapted from Paxinos & Watson rat brain atlas 2005). 
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2.8 In vivo sleep studies 
 
2.8.1 Animal preparation 
 
Adult, male Wistar rats (250-300g) were anesthetized (2% isoflurane in 100% oxygen) and 
surgically prepared with a cranial implant that permitted chronic electro-encephalogram (EEG) 
and electromyogram (EMG) recording. Body temperature and locomotor activity were 
monitored via a miniature transmitter (Minimitter PDT4000G, Philips Respironics, Bend, OR) 
surgically placed in the abdomen during the same anesthetic event in which the cranial 
portion was implanted. The cranial implant consisted of stainless steel screws (2 frontal [+3.5 
AP from bregma, ±2.0 ML] and 2 occipital [-6.5 AP, ±5.2 ML]) for EEG recording (Fig.2.10). Two 
Teflon-coated stainless steel wires were positioned under the nuchal trapezoid muscles for 
electromyography (EMG) recording. All leads were crimped to a miniature connector 
(Omnetics, Minneapolis, MN, USA) and gas sterilized with ethylene oxide prior to surgery. The 
implant assembly was affixed to the skull by the combination of the EEG recording screws, 
cyanoacrylate applied between the hermetically sealed implant connector and skull, and 
dental acrylic. An analgesic (buprenorphine 0.05 mg/kg) was administered subcutaneously 
pre-operatively, at the end of the surgery day, and the morning of the first post-operative day. 
To provide additional pain relief, meloxicam 0.15 mg/kg was administered orally twice daily 
for 6 days post-surgery. The antibiotic cefalexin 20 mg/kg was administered orally 24 hours 
prior to and immediately before surgery, and twice daily for 7 days after surgery. At least 3 
weeks were allowed for recovery. 
 
2.8.2 Recording environment 
 
Each rat was housed individually within a specially modified Ancare™ microisolator cage 
(Ancare, Bellmore, NY, USA) having a custom polycarbonate filter-top riser and an ultra-low-
torque slip-ring commutator (Hypnion Inc., Lexington, MA, USA). A custom engineered flexible 
tether connected at one end to the commutator and at the other end to the animal’s cranial 
implant. Each cage was located within separate, ventilated compartments of a stainless steel 
sleep-wake recording chamber, and had an infrared light source and digital video camera to 
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allow a minimum of twice daily remote visual monitoring. Food and water were available ad 
libitum, and the ambient temperature was 23±1°C. A 24-hr light-dark cycle using fluorescent 
light was maintained and monitored throughout the study. Light intensity averaged 35-40 lux 
at mid-level inside the cage. Relative humidity averaged 50%. Animals were undisturbed for 48 
hours before and after each treatment. 
 
2.8.3 Data collection 
 
Sleep and wakefulness were determined using SCORE-2000™ (hereinafter called SCORE) a 
validated microcomputer-based sleep-wake and physiological monitoring system (Al-Shamma 
et a., 2010). The system monitored amplified EEG (X10,000, bandpass 1-30 Hz [Grass Corp., 
Quincy, MA, USA]; initial digitization rate 400 Hz), integrated EMG (bandpass 10-100 Hz, RMS 
integration), and telemetered body temperature and non-specific locomotor activity, and 
drinking activity. Arousal states were classified on-line as NREM sleep, REM sleep, wake, or 
theta-dominated wake every 10 seconds using EEG period and amplitude feature extraction 
and ranked membership algorithms. Individually taught EEG-arousal-state templates and EMG 
criteria differentiated states of arousal. A fast Fourier transform (FFT) was used to calculate 
the spectral power of EEG in each epoch in 0.1 Hz bins. Time series of EEG power in each of 4 
bands (delta 0.1-3.9 Hz, theta 4.0-8.9 Hz, alpha 9.0-11.9 Hz, beta 12.0-20.0 Hz) was calculated 
for all EEG-defined NREM epochs devoid of artifact. Locomotor, drink-related, and food-
related activities were automatically recorded as counts per minute, and body temperature 
was recorded each minute. Locomotor activity was detected in both horizontal and vertical 
planes by a customized telemetry receiver (ER4000, Minimitter Inc., Bend, OR, USA) beneath 
the cage. Drink-related and food-related activities were detected by beam break sensors 
closely situated around recessed access portals to the lixit and the food bin, respectively.  
 
Telemetry measures (locomotor activity and body temperature) were not part of the SCORE 
arousal-state determination algorithm; thus, sleep-scoring and telemetry data were 
concurrent but independent measures. In addition to frequent on-line inspection of the EEG 
and EMG signals, quality control of the data was assured by expert analysts using a suite of 
programs (ScoreView™, Lilly proprietary software, described below) that allowed data quality 
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of all variables to be flexibly scrutinized at the level of (1) individual visual examination of raw 
EEG and EMG signals, (2) individual hourly mean time-series, and (3) group mean time series, 
using a combination of graphical and statistical assessments. An integrated relational database 
was updated with data quality control decisions for each individual treatment, and this 
database controlled all subsequent use of these data.   
 
2.8.4 Data processing  
 
Files of digitized EEG/ EMG data were subject to offline processing. ScoreView™ quality control 
software allowed EEG-arousal-state templates and EMG criteria to be individually taught and 
optimized offline, using the pre-treatment baseline portion of a file. It also concurrently 
provided detailed flexible EEG/EMG visualizations, overviews including locomotor activity and 
body temperature, FFT, statistics and artifact information for the file being reviewed. 
Templates were optimized after the first week an animal was online, with occasional further 
minor optimizations in subsequent weeks. If a template was optimized, the data file was re-
scored using the new template. Only the pre-treatment baseline portion of the file was used 
for scoring optimization. Based on these individual animal data evaluations, preliminary 
quality control judgments were recorded in the database. ScoreView™ then permitted time 
series overlay plots of all individuals in a treatment group, allowing visualization of individual 
‘outliers’ in any time series for any variable. Outliers were subject to additional scrutiny 
facilitated by ScoreView™ to determine whether the underlying data contained unacceptable 
artifacts. Final quality control judgments were then entered into the database and controlled 
all subsequent use of the data. A team of experts (≥3 years of experience) conducting these 
analyses were not blind to the treatment, but they were independent of the persons 
producing the data and of the project scientists using the data. 
 
2.8.5 Study design and analysis 
 
Mepyramine (1mg/kg) was studied 5 hours after lights on (CT-5, Fig. 2.11). Dosing during lights 
on was necessary as the tail vein was not visible during lights off (even under red light).  The 
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compound was characterised in a parallel group study design. Drug treatments were pseudo-
randomised. The total amount of REM sleep, NREM sleep, and total sleep were calculated in 
the 7 hours following dosing (CT-5 to CT-12). The longest sleep bout in the 7 hours following 
dosing was also calculated. In each of the 7 hours following dosing the average sleep bout 
length was calculated, and then the average of these 7-hour averages was calculated. 
Corresponding calculations were made 24 hours earlier as baseline variables. The latency to 
the first 30 continuous seconds of any sleep (3 consecutive epochs), first 60 continuous 
seconds of any sleep (6 consecutive epochs), and first 20 continuous seconds of REM sleep (2 
consecutive epochs) was calculated. No baseline variables were calculated for latency 
variables. Total locomotor activity counts were calculated for the 12 hour lights off period (CT-
12 to CT-24). This was divided by the total amount of wake time in that period to derive a 
measure defined as locomotor intensity. Total sleep time is also reported. Baseline measures 
were calculated for all 3 variables (locomotor activity counts, wake time, and locomotor 
intensity). 
  
2.9 Reagents and drugs: in vivo studies 
 
All chemicals are listed in Table 1.2 with the corresponding site of action, dose used, vehicle 
solution and the company from which they were obtained. Briefly solutions were dissolved in 
0.9% NaCl saline, HBCD, or 0.25% MC. All drugs were purchased from Sigma Aldrich (Dorset, 
UK), National Vetenary Supplies (NVC, Stoke-on-Trent, UK) or obtained from Eli Lilly (IN, USA). 
Where required, all drug formulations occurred immediately before each treatment, the only 
exception was for urethane which was made up each week. Each compound was added to its 
corresponding vehicle and where required was mixed using a sterile ground glass mortar and 
closely fitting pestle (i.e. tissue homogeniser) until finely suspended. Solutions were agitated 
immediately before being drawn into a syringe. For sleep studies, to administer the treatment 
each rat was removed from its cage for approximately 60-90s to be weighed and treated. 
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Figure 2.10. Rat skull with cranial implant. Dorsal and lateral views of the skull of a 290g 
Wistar rat with a cranial implant (blue). Four stainless steel screws (2 frontal and 2 occipital) 
allowed EEG recording and two stainless steel wires positioned under the nuchal trapezoid 
muscles allowed EMG recording. 
 
 
 
 
 
 
Figure 2.11. 60 hour circadian time scale. Animals were given an i.v. Injection of drug at 
circadian time 5 (CT-5). Sleep-wake variables (wake, NREM, REM) and locomotor activity were 
monitored for 60 hours in total (29 hours pre-dosing and 31 hours post-dosing).  
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2.10 Statistical analysis  
 
Data are presented as the arithmetic mean ± standard error of the mean (SEM) and values of n 
refer to the number of independent cells tested in each group. The statistics software IBM 
SPSS (version 21) was used to carry out all of the statistical tests reported. Where appropriate 
a Student’s t-test (paired or unpaired), ANOVA (with or without repeated measures design), 
ANCOVA or General Estimating Equation with clustering (GEE) test was carried out. Note, GEE 
is an extension of ANOVA which enables clustering of data sets when required e.g. data 
obtained from multiple slices from a single brain can be clustered together in order to assign 
each slice as an n of 1 (rather than assigning a brain to an n of 1). Post hoc tests were also 
carried out where appropriate. Details of the relevant statistical tests used to determine the 
effect of each drug are described within the relevant results section. 
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Chapter 3: 
Regulation of dorsal raphe neurons in vitro 
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3.1 Introduction 
 
The DRN contains one of the largest groups of serotonergic neurons in the brain and is the 
principle source of serotonergic innervation of the forebrain. Early in vivo electrophysiological 
studies demonstrated that DRN serotonergic neurons displayed remarkably consistent 
pharmacological and electrophysiological characteristics. These cells were shown to exhibit 
slow (0.3-4Hz), regular, spontaneous activity, to fire broad action potentials (3-4ms duration) 
followed by a prominent after-hyperpolarisation, and to be inhibited by 5-HT (Aghajanian and 
Vandermaelen, 1982a, 1982b). Moreover in vitro recordings made from 5-HT neurons in the 
DRN demonstrated that the electrophysiological characteristics of these neurons were 
indistinguishable from 5-HT neurons recorded in vivo (Mosko & Jacobs, 1976; Vandermaelen & 
Aghajanian, 1983). These criteria became accepted hallmarks of serotonergic neurons and 
were viewed as necessary and sufficient for neuronal identity. This has permitted the 
distinction between 5-HT and non-5HT neurons (e.g. GABA and glutamate) within the DRN and 
has enabled the study of how 5-HT neurons could be regulated. Importantly it has been 
demonstrated that serotonergic neurons are not only under regulatory control by local, inter-
raphe mechanisms but also by afferent inputs from neurotransmitters systems located 
throughout the brain. Noradrenergic neurons from the locus coeruleus are thought to provide 
an important tonic input to 5-HT neurons within the DRN which maintains the firing level of 
these neurons (Baraban and Aghajanian, 1980; Baraban and Aghajanian, 1981). In addition 
orexin neurons from the posterior hypothalamus have been shown to excite 5-HT neurons 
within the DRN and this has been implicated in regulating these neurons during wakefulness 
(Brown et al., 2001). This chapter has focussed on investigated how the electrophysiological 
output from DRN 5-HT neurons can be regulated by specific neurotransmitters and peptides 
including: 5-HT, phenylephrine and orexin.  
 
3.2 Electrophysiological and pharmacological characterisation of DRN neurons 
 
3.2.1 Electrophysiological characterisation of spontaneously firing 5-HT neurons 
 
Using the extracellular recording configuration 25 spontaneously firing neurons were recorded 
from the midline of the DRN. Twenty two of these neurons (87.5%) satisfied all of the criteria 
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required to classify them as putative 5-HT neurons. A representative action potential (spike) 
from a putative 5-HT neuron can be seen in Figure 3.1. Overall these neurons fired bi-phasic 
(positive-negative), broad action potentials (3.56 ± 0.87ms, Fig 3.1.A1) in a highly regular 
pattern, as evident by the low CV value (0.29 ± 0.04, Fig 3.1.A2) and with low frequency (2.05 ± 
0.32Hz, Fig 3.1.A3). A small subset of neurons recorded (12.5%) also displayed bi-phasic, broad 
action potentials (3.52 ± 0.84ms) with a highly regular firing pattern (0.14 ± 0.3) however 
these neurons fired at a much higher frequency (7.84 ± 0.55Hz, Fig 3.1B). Although it is 
historically thought that “fast firing” neurons (frequency >4.5Hz) located along the midline of 
the DRN are non-5-HT there is evidence to suggest that a portion may in fact be 5-HT neurons 
(Allers and Sharp, 2003).  As there was no possibility of confirming the neurochemical identity 
of these cells all subsequent extracellular experiments were performed on “slower firing”, 
putative 5-HT neurons.   
 
Note that these experiments were performed on tissue derived from mice P16-27 of either 
sex. At this age mice are sexually immature but contain a fully developed raphe serotonin 
system (Deng et al., 2007). In addition data were collected from more than one brain slice per 
animal. In order to investigate whether age and/or gender may have had a significant effect on 
the electrophysiological criteria of putative 5-HT (spike duration, CV or firing frequency) 
Generalised Estimating Equation (GEE) analyses were performed. In the GEE test age and 
gender were included as factors and brain slices were included as a subject variable. There was 
no significant effect (p > 0.05) of age or gender on the spike duration, CV or firing frequency 
therefore data was pooled from both genders and all ages. 
 
3.2.2 Electrophysiological characteristics of 5-HT neurons are regulated by phenylephrine 
 
It is well documented that 5-HT neurons within the DRN receive tonic excitatory input from 
noradrenergic neurons of the locus coeruleus (Pan et al., 1994, Sakai and Crochet, 2000). 
During the brain slicing process these noradrenergic afferents are severed causing a reduction 
or complete cessation of firing from 5-HT neurons in the DRN. The α1-adrenoreceptor agonist 
phenylephrine can be used to restore 5-HT neuronal firing to levels similar to those seen in 
vivo (Smith and Gallager, 1989, Vandermaelen and Aghajanian, 1983). Here we used 
phenylephrine to restore the role of the noradrenergic input into the DRN. 
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Using the extracellular recording configuration a total of 43 putative 5-HT neurons were 
recorded in the presence of phenylephrine (10µM). When the electrophysiological 
characteristics of 5-HT neurons are compared in the absence and presence of phenylephrine it 
can be seen that neurons recorded in the presence of phenylephrine fire at a significantly 
faster frequency (2.77 ± 0.13Hz, Fig 3.2A) and in a more regular firing pattern (CV = 0.16 ± 
0.02, Fig 3.2B). Note that these two populations of neurons are unpaired. A table summarising 
all of the neurons recorded under these conditions can be seen in Fig 3.2C. A qualitative 
observation noted during these experiments was that, as one may expect, it was easier to 
locate firing neurons in the slice when phenylephrine was present.  
 
As these experiments were carried out on tissue derived from mice P16-27 of either sex GEE 
analyses were carried in order to check whether age and gender may have an effect on the 
spike duration, CV or firing frequency of phenylephrine-driven 5-HT neurons. In the GEE test 
age and gender were included as factors and brain slices were included as a subject variable. 
In addition phenylephrine was also added as a factor to determine if it had a significant effect 
on any of the measurements. There was no significant effect (p > 0.05) of age or gender on the 
spike duration, CV or firing frequency therefore data were pooled from both genders and all 
ages. When GEE analysis was run with drug (PE) as a factor it can be seen that phenylephrine 
has a significant effect on the CV (p < 0.05) and firing frequency (p < 0.05) but no significant 
effect on the spike width (p > 0.05).  
 
3.2.3 Pharmacological characterisation of 5-HT neurons with 5-HT 
 
In addition to the electrophysiological characterisation described above putative 5-HT neurons 
recorded in the DRN have been pharmacologically characterised as being inhibited by 5-HT 
(Vandermaelen and Aghajanian, 1983). This 5-HT-induced inhibition has been shown to occur 
via the 5-HT1A autoreceptor located on the soma and dendrites of 5-HT neurons (Judge and 
Gartside, 2006, Sprouse and Aghajanian, 1986). Here we investigated the effect of 5-HT on 
neurons within the DRN.  
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Utilising the extracellular recording configuration a total of 39 putative 5-HT neurons were 
tested with varying concentrations of 5-HT (1, 3, 10 and 30µM). All of these neurons were 
recorded in the presence of 10µM phenylephrine. Thirty seven neurons were inhibited by 5-HT 
in a concentration-dependent manner with an IC50 = 7.2µM (Fig 3.3.A). One neuron was 
excited by 5-HT (3 and 10µM; p < 0.05, paired Student’s t-test) and one neuron did not 
respond (10 and 30µM; p > 0.05, paired Student’s t-test). Application of 10µM 5-HT to neurons 
revealed a wide range of inhibition from 12-100% (Fig 3.3.B). A representative recording of the 
firing frequency in the absence and presence of 10µM 5-HT can be seen in Figure 3.3.C. The 
inhibitory effect of all concentrations 5-HT were reversible (data not shown). 
 
GEE analyses were carried out to assess whether 5-HT had a significant effect on cell firing. 
Age, gender and 5-HT concentration were included as factors and brain slices were included as 
a subject variable. Analysis carried out on the absolute values revealed that 3, 10 and 30µM 
had a significant effect of the firing frequency (p < 0.01) whereas analysis carried out on the 
normalised data revealed that all concentrations of 5-HT had a significant effect on firing (p < 
0.05).  
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Figure 3.1. Extracellular characterisation of 5-HT neurons in the DRN. (A1) A representative 
biphasic, broad-width action potential (spike) recorded from the midline of the DRN. (A2) A 
representative interevent-interval histogram (in 25ms bins) indicating a very regular firing 
pattern (CV = 0.27). (A3) A representative 10 second section of the spike train. (B) A table 
summarising the electrophysiological properties analysed to establish 5-HT neuronal identity. 
Values are displayed as the average ± SEM. Values in parentheses represent the range of 
values. 
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Figure 3.2. A comparison of 5-HT neuronal characteristics in the presence and absence of 
phenylephrine. (A) A scatter plot of the average firing frequency of putative 5-HT neurons in 
the absence and presence of the α1-adrenoreceptor agonist phenylephrine, PE (10µM). The 
horizontal line denotes the average value. (B) A bar graph depicting the average coefficient of 
variation (CV) associated with recordings performed either in the presence or in the absence 
phenylephrine (PE). (C) A table summarising the electrophysiological characteristics of 5-HT 
neurons in the presence and absence of phenylephrine. Values are displayed as the average ± 
SEM. Values in parentheses represent the range of values. Note that 5-HT neurons recorded in 
the presence of 10µM phenylephrine fire at a significantly faster frequency and in a more 
regular pattern i.e. lower CV. *p < 0.05, GEE analysis.     
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Figure 3.3. 5-HT inhibits in a concentration-dependent manner the firing of putative 5-HT 
DRN neurons. (A) A plot illustrating the 5-HT concentration-dependent inhibition of DRN 
neuronal firing. Firing frequency of putative 5-HT DR neurones (expressed as % of control) is 
plotted on the Y axis as a function of increasing concentration of 5-HT on the x axis (log scale). 
The corresponding IC50 value is given to the right of the curve and was obtained from non-
linear regression analysis. Note that 5-HT causes concentration-dependent inhibition of firing 
with an IC50 equal to 7.2 ± 0.1 µM. (B) Left: Firing frequency of individual putative 5-HT 
neurons (open circles) in the absence (control) and presence of 5-HT (10μM). The average 
firing frequency in control and in the presence of 5-HT is shown by the closed circles (mean ± 
SE). Right: A representative recording of the firing frequency (20s bins) from a phenylephrine-
driven 5-HT neuron in the presence of 10µM 5-HT. 
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3.3 Regulation of 5-HT neuronal firing by 5-HT2  receptors 
 
It has been well established that somatodendritic 5-HT1A autoreceptors located on 5-HT 
neurons provide an important local feedback regulation within the DRN (Aghajanian and 
Lakoski, 1984, Williams et al., 1988). In addition to 5-HT1A receptor regulation, mounting 
evidence has emerged implicating postsynaptic 5-HT2 receptors in the  5-HT-mediated 
feedback regulation of DRN activity (Boothman et al., 2003, Garratt et al., 1991, Kidd et al., 
1991, Wright et al., 1990). Immunohistochemistry (Boothman and Sharp, 2005) and in situ 
hybridisation studies (Serrats et al., 2005) have shown that 5-HT2 receptors are located on 
local GABAergic neurons which synapse onto 5-HT neurons. In support of these findings, an 
electrophysiological investigation in rat brain slices demonstrated the bath application of 5-HT 
or DOI (a mixed 5-HT2A/2C agonist) increased the frequency of GABA-mediated synaptic 
currents in 5-HT cells (Liu et al., 2000). Here I utilised extracellular and whole-cell voltage-
clamp recordings to assess the role of 5-HT2Rs in the regulation of mouse DRN neuronal 
activity by 5-HT and explored a putative contribution by GABAergic neurons. 
 
3.3.1 Selective 5-HT2 receptor antagonists do not alter 5-HT-induced inhibition 
 
All recordings described below were performed in the presence of phenylephrine. Utilising the 
extracellular single-unit recording configuration neurons were initially challenged with 5-HT 
(10µM) to establish the neuron sensitivity to 5-HTR activation. After complete washout either 
a selective 5-HT2A receptor (MDL 100907, 30nM) or a selective 5-HT2C (SB 242084, 30nM) 
antagonist was applied. 5-HT (10µM) was subsequently applied in the presence of each 
antagonist and the ensuing response compared with that initially established in the absence of 
the antagonist. (Fig.3.2.1). 5-HT application produced a reduction of firing in both treatment 
groups (Fig3.4). Application of either antagonist MDL 100907 (Fig.3.4A) or SB 242084 (Fig.3.4B) 
in the absence of 5-HT did not affect the firing of neurons (see Fig.3.2.1A and Fig.3.2.1B for 
MDL 100907 and SB 242084 respectively). Furthermore neither antagonist was able to alter 
the 5-HT response.   
 
A one-way repeated measures ANOVA (with drug treatment as the within-subjects factor) 
performed on the normalised data revealed a significant main effect of drug application on the 
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percentage of control firing (F(4,8) = 8.091; p < 0.01). In order to see if 5-HT application was 
significantly different from MDL + 5-HT application pairwise comparisons were performed 
using Bonferronni correction. No significant difference was revealed. This statistical analysis 
was repeated for cells which received SB 242084 treatment. A one-way repeated measures 
ANOVA performed on the normalised data revealed a significant main effect of drug 
application (F(4, 8) = 17.734; p < 0.01). Pairwise comparisons using Bonferronni correction 
were performed. No significant different was revealed between 5-HT application and SB + 5-
HT application.  
 
3.3.2 Direct activation of 5-HT2 receptors caused inhibition of 5-HT neuronal firing 
  
To investigate the role of 5-HT2 receptors in the DRN further we applied the mixed 5-HT2A/2C 
agonist, DOI to slices treated with phenylephrine (10μM).  Using the extracellular single-unit 
recording technique, 5 putative 5-HT neurons were tested with 10µM DOI (Fig.3.5). A 
representative recording from a putative 5-HT neuron is illustrated in Fig3.5A. Application of 
DOI caused the firing frequency of the cell to decrease rapidly until it reached a stable plateau. 
When the control firing frequency is compared with the firing frequency in the presence of 
DOI we can see clearly that in each cell tested that DOI induces a significant inhibition 
(Fig3.2.5B1). When expressed as a percentage of control it can be seen that DOI caused a 
significant inhibition (53.2%, p < 0.05, paired Student’s t-test) of cell firing across all 5 cells 
tested (Fig3.2.5B2).            
 
3.3.3 DOI prolongs the decay kinetics of DRN IPSCs  
 
Electrophysiological studies have demonstrated that 5-HT2A/2C receptors are located on 
GABAergic neurons which synapse onto 5-HT DRN neurons (Liu et al., 2000). In order to better 
understand the DOI-induced inhibition of 5-HT neurons we investigated the properties of 
sIPSCs and mIPSCs recorded in the absence and presence of DOI. Using the whole-cell voltage-
clamp configuration and conditions described in the material and methods (section 2.6) sIPSCs 
and mIPSCs were recorded from DRN 5-HTneurons voltage-clamped at -60mV, in the presence 
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of 2mM kynurenic acid and 0.5µM strychnine. Under these conditions IPSCs are evident as 
inward currents (i.e. downward deflections from the baseline (Figure.3.6).  
A summary of the properties of sIPSCs and mIPSCs (Fig3.7A) reveal that the peak amplitude, 
rise time and frequency are not significantly affected by DOI (10µM). The T70 value of sIPSCs is 
longer in the presence of DOI (p < 0.05, paired Student’s t-test). The T70 value of mIPSCs is 
also longer in the presence of DOI (p < 0.05, paired Student’s t-test). In support the decay time 
constant of mIPSCs was also significantly longer in the presence of DOI (p < 0.05, paired 
Student’s t-test). An averaged GABAA receptor mediated sIPSC (Fig.3.7B left) and mIPSC 
(Fig.3.7B right) in the absence and presence of 10µM DOI illustrates the prolongation of the 
decay kinetics.  
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Figure 3.4. Selective antagonists of 5-HT2 receptors have no effect on 5-HT-induced 
inhibition of DRN neuronal firing. (A) 5-HT (10µM) caused an inhibition of cell firing. After 
washout the 5-HT2A antagonist, MDL 100907 (30nM) was applied the cells were re-tested with 
5-HT (n = 3). (B) 5-HT (10µM) caused an inhibition of cell firing. After washout the 5-HT2C 
antagonist, SB 24204 (30nM) was applied the cells were re-tested with 5-HT (n = 3). Neither 
antagonist caused a change in the firing of neurons and neither antagonist was able to alter 
the 5-HT response (p > 0.05, One-way repeated measures ANOVA with Bonferonni analysis).  
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Figure 3.5. The 5-HT2 receptor agonist DOI inhibits the firing of putative 5-HT neurons. (A) A 
representative recording of the firing frequency (20s bins) from a phenylephrine-driven 5-HT 
neuron in the presence of 10µM DOI. (B) Firing frequency of individual putative 5-HT neurons 
(open circles) in the presence of 5-HT (10μM) before (control) and after the application of DOI 
(10µM). The average firing frequency in control and in the presence of DOI is shown by the 
closed circles (mean ± SE). (C) Bar graph showing the average effect of DOI when applied to 
phenylephrine-driven 5-HT neurons. Effect is displayed as a mean percentage of the control 
firing frequency ± SEM. Values in parenthesis denote the number of DOI applications. *p < 
0.05 and ** p < 0.01 paired Student’s t-test.      
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Figure 3.6. GABA receptor synaptic events recorded from a putative 5-HT neuron in the DRN. 
A representative whole-cell voltage-clamp (-60mV) recording (60s) of a neuron in the presence 
of 2mM kynurenic acid and 0.5µM strychnine. GABA receptor synaptic events are evident as 
downward deflection from the baseline. 
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Figure.3.7. GABA receptor synaptic events recorded from putative 5-HT neurons in the DRN.  
(A) Table comparing the properties of sIPSCs and mIPSCs in the presence and absence of DOI 
(10µM). * p < 0.05 and ** p < 0.01  paired Student’s t-test. (B) A representative trace of an 
averaged GABAA receptor mediated sIPSC (left ) or mIPSC (right) recorded in the absence 
(black) and presence (grey) of DOI.  
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3.4 Regulation of 5-HT neuronal firing by orexin 
 
Orexin-containing neurons (orexin-A and orexin-B) from the lateral hypothalamus densely 
innervate 5-HT neurons in the DRN (Peyron et al., 1998a; Lee et al., 2005b). Orexin-A and 
orexin-B elicit their effects through two G-protein coupled receptors OX1 and OX2 both of 
which are present in the DRN (Marcus et al., 2001). In vivo extracellular recordings 
demonstrate that orexin excites putative 5-HT neurons in the DRN (Takahashi et al., 2005) and 
in vitro studies indicate this excitation is mediated via a non-selective cationic conductance 
(Brown et al., 2002; Liu et al., 2002; Kohlmeier et al., 2008). Here I utilised extracellular and 
whole-cell voltage-clamp recordings to investigate the role of OX1/2Rs in the regulation of 
mouse DRN neuronal activity.  
 
3.4.1 Orexin-A excites putative 5-HT neurons in the DRN 
 
Using the extracellular single-unit recording technique, 7 putative 5-HT neurons were tested 
with 100nM orexin-A (Fig.3.8). A representative recording from a putative 5-HT neuron is 
illustrated in Fig.3.8.A. Application of orexin caused the firing frequency of the cell to increase 
rapidly until it reached a stable plateau. When the control firing frequency is compared with 
the firing frequency in the presence of orexin we can noticeably see that in each cell tested  
orexin induces significant excitation (Fig.3.8.B). When expressed as a percentage of control 
(normalised data) it can be seen that orexin causes a significant excitation (393 ± 57%, p < 
0.01, paired Student’s t-test) of cell firing across all 7 cells tested. 
 
3.4.2 Orexin-A induces a large inward current in putative 5-HT neurons in the DRN 
 
In order to further investigate the role of orexin-A in the DRN I utilised the whole-cell voltage-
clamp recording technique. Experiments were performed at a holding potential of -60mV with 
a KGluconate intracellular solution (see section 2.6). In 12/12 neurons (100%) orexin-A 
produced an inward current (-25 ± 4pA, p < 0.001 paired Student’s test) and an increase in the 
RMS (2 ± 0.4pA, p < 0.01 paired Student’s t-test). In seven neurons, the dual OX1/2R antagonist 
almorexant was bath applied after the orexin-induced current had reached a stable plateau. A 
representative voltage-clamp recording is illustrated in Fig.3.9.A. It can be seen that bath 
79 
 
 
application of 100nM orexin-A produces an inward current which is reversed by the 
subsequent application of 1µM almorexant. When the average change in holding current (-24 
± 4pA, Fig.3.9.B left) and RMS (+23 ± 4pA, Fig.3.9.B right) are graphed we can see that 
almorexant completely reverses the effect of orexin. A one-way repeated-measures ANOVA 
was conducted to compare the effect of drug treatments on the holding current and RMS. 
There was a significant main effect of drug treatment on holding current (F(1.17, 7.092) = 
5.504; p < 0.05) and RMS (F(1.645,10.087) = 9.720; p < 0.01)  therefore post hoc t-test were 
performed. Post hoc, paired t-tests indicated that orexin application was significantly different 
from control for holding current (p < 0.01) and RMS (p < 0.05) values whereas almorexant was 
not significantly different (p > 0.05) for either. This confirms that almorexant is able to fully 
reverse the effects of orexin-A. 
 
3.4.3 Almorexant application does not reveal a tonic orexin conductance in the DRN 
 
Given the large effect of orexin-A on putative 5-HT neurons in the DRN I wanted investigate 
whether a tonic orexin conductance may be present in these neurons. In order to assess this 
possibility I performed whole-cell voltage-clamp recordings and bath applied 1µM almorexant 
followed by 100nM orexin. A representative voltage-clamp (VH = -60mV) recording can be seen 
in Fig.3.10.A. The holding current was not attenuated by the application of almorexant and 
furthermore remained unaffected by the additional application of orexin. When the average 
change in holding current (Fig.3.10.B left) and RMS (Fig.3.10.B right) are graphed it can be 
seen that almorexant and orexin do not have an effect on either measurement (n = 5). A one-
way repeated measures ANOVA confirmed that this drug treatment did not produce a 
significant effect on holding current (F(1.548,6.192) = 3.704; p = 0.93) or RMS (F(1.338,5.350) = 
2.631; p = 0.162).   
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Figure 3.8. Orexin increases the firing of putative 5-HT neurons. (A) A representative 
extracellular singe-unit recording of the firing frequency (20s bins) from a spontaneously firing 
neuron in the presence of 100nM orexin. (B) Left: firing frequency of individual neurons (open 
circles) before (control) and after the application of orexin (100nM). The average firing 
frequency in control and in the presence of histamine is shown by the closed circles (mean ± 
SEM). Right: Bar graph showing the average effect of histamine when applied to 
spontaneously firing 5-HT neurons (n = 7). Effect is displayed as the mean percentage of 
control firing frequency ± SEM. *** p < 0.01, paired Student’s t-test.  
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Figure 3.9. Orexin induces an inward current which is reversed by the OX1/2R antagonist, 
almorexant. (A) A representative recording (VH = -60mV) from a putative 5-HT neuron 
illustrating the inward current induced by the bath application of 100nM orexin and the 
subsequent reversal by almorexant. The corresponding all-points histograms are given to the 
right. (B) A bar graph summarising the changes in holding current (left) and RMS (right) evoked 
by the bath application of orexin and almorexant (n = 7). Error bars indicate SEM.  
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Figure 3.10. Almorexant blocks the effect orexin and fails to demonstrate an endogenous 
orexin tone. (A) A representative recording (VH = -60mV) from a putative 5-HT neuron 
illustrating that the bath application of 1µM almorexant does not reveal an endogenous orexin 
tonic current but does block the subsequent application of 100nM orexin. (B) A bar graph 
summarising the changes in holding current (left) and RMS (right) evoked by the bath 
application of almorexant and orexin (n = 6). Error bars indicate SEM.  
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3.5 Discussion 
 
3.5.1 Electrophysiological characterisation of putative 5-HT neurons in the DRN 
 
Extracellular single-unit recordings performed from putative 5-HT neurons in the DRN revealed 
that these neurons fired slow (2.1 ± 0.3Hz), rhythmic, bi-phasic action potentials (3.6 ± 0.3ms). 
These electrophysiological data are consistent with previous studies performed in vitro in mice 
(Trulson & Crisp, 1986) and rats (Mosko & Jacobs, 1976; Aghajanian & Vandermaelen, 1982b; 
Vandermaelen & Aghajanian, 1983). Extracellular recordings also revealed that putative 5-HT 
neurons in the DRN are spontaneously active in vitro. The observation of spontaneous firing in 
the DRN is somewhat inconsistent in vitro with some studies reporting high levels (Macri et al., 
2006), low levels (Vandermaelen & Aghajanian, 1983; Kirby et al., 2003) or no spontaneous 
firing at all (Beck et al., 2004). The intrinsic pacemaker property of 5-HT neurons 
(characterised by a pronounce AHP, followed by a gradual interspike depolarisation) is known 
to be produced by a calcium-activated potassium current (Aghajanian, 1985; Crunelli et al., 
1983; Burlhis & Aghajanian, 1987). It is therefore possible that the discrepancy between 
spontaneously active and silent neurons across these studies is due to differences in the 
extracellular Ca2+ concentration. The level of extracellular Ca2+ in the slice is dependent upon 
the slicing and recording conditions i.e. the level of Ca2+, presence of Ca2+ chelators and pH and 
will hence vary between studies. A small proportion of fast-firing neurons (7.8 ± 0.6Hz) were 
also observed in this study. These neurons fired rhythmic, bi-phasic action potentials (3.5 ± 
0.8ms) very similar to those which fired at a slower rate. Historically these neurons were 
classified as non-serotonergic (most likely GABAergic) however recent electrophysiological 
studies conducted in combination with immunohistochemistry have revealed that a portion of 
these faster firing neurons are in fact serotonergic (Allers & Sharp, 2003). Similar to the results 
present here, these fast firing 5-HT neurons had electrophysiological characteristics almost 
identical to slower firing 5-HT neurons (rhythmic, broad, bi-phasic action potentials). Given 
that this population of fast firing 5-HT neurons has been excluded from extensive study it will 
be important in the future to understand exactly what role these neurons have within the 
DRN.  
 
In vivo DRN serotonergic neurons are spontaneously active however, as noted above, the 
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number of neurons showing spontaneous activity is markedly reduced when recording in vitro. 
This suggests that the spontaneous activity of the DRN 5-HT neurons is dependent on intact 
afferent drive, most likely originating from noradrenergic neurons of the locus coeruleus 
(Baraban & Aghajanian, 1980; Baraban & Aghajanian, 1981; Vandermaelen & Aghajanian, 
1983). When the spontaneous firing properties of DRN 5-HT neurons were compared with the 
firing properties during phenylephrine application it was observed that the firing frequency 
was significantly higher in the phenylephrine-driven 5-HT neurons (2.1Hz verses 2.8Hz). In 
addition the number of active neurons per slice was much higher in the presence of 
phenylephrine. It therefore appears that 5-HT DRN neurons possess intrinsic pacemaker 
potentials, however, for most of these neurons the expression of these spontaneous 
potentials is dependent upon the presence of excitatory inputs. These inputs can be provided 
by noradrenergic synaptic input as occurs in vivo, or by the exogenous application of 
phenylephrine, as was done in the present study. Given the results from this study were 
provided from two separate groups of neurons it would be interesting to test the direct effect 
of adding phenylephrine to spontaneously firing neurons to assess what proportion of neurons 
would respond and to what degree. Furthermore it would be interesting to observe the effect 
of applying an α1 adrenoreceptor antagonist to spontaneously firing neurons in vitro.   
 
Pharmacological characterisation of DRN 5-HT neurons with bath applied 5-HT revealed that 
the majority of neurons (37/39) were inhibited by 5-HT in a concentration-dependent manner. 
This 5-HT-induced inhibition of firing is consistent with previous studies which applied 5-HT to 
rat brain slices (Vandermaelen & Aghajanian, 1983; Judge & Gartside, 2006). In addition a 
small minority of neurons were not inhibited by 5-HT, instead one neuron failed to respond to 
5-HT and one was excited. This heterogeneous response to 5-HT has been reported previously 
in DRN 5-HT neurons recorded from rat brain slices although a slightly higher proportion of 
neurons were excited by 5-HT than was observed here (Judge & Gartside, 2006). Although not 
investigated directly here, previous studies have revealed that 5-HT produces its inhibitory 
effect by activating 5-HT1A autoreceptors located on the soma and dendrites of 5-HT neurons 
(Aghajanian & Lakoski, 1984; Sotelo et al., 1990). Subsequent work has revealed differing 5-
HT1A receptor sensitivity across different subfields of the DRN (Calizo et al., 2011). This 
heterogeneous 5-HT1A receptor sensitivity could account for the wide range of 5-HT-induced 
inhibition observed here. It should be noted however that GABAergic interneurons in the DRN 
are also known to express 5-HT1A autoreceptors (Bonnavion et al., 2010). Studies which have 
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combined electrophysiological recordings with immunohistochemistry have revealed that 
some GABAergic neurons are indistinguishable from 5-HT neurons based on their firing 
properties alone (Beck et al., 2004; Calizo et al., 2011). It is therefore plausible that some 
neurons recorded in this study could be GABAergic. The likelihood of misidentification of 
neurons was reduced in this study by making recordings from the midline of the DRN, where 
the neurons are predominantly serotonergic (Beck et al., 2004; Brown et al., 2008; Calizo et 
al., 2011). A recent study has also reported on the existence of a subpopulation of DRN 5-HT 
neurons which do not express 5-HT1A receptors (Kiyasova et al., 2013). This could account for 
the lack of 5-HT effect seen in one neuron. These studies, taken together, suggest that 
different functional subclasses of 5-HT neurons exist within the DRN and in light of this, great 
care should be taken when interpreting any results which have not been supported by 
immunohistochemical work.  
 
3.5.2 Regulation of putative 5-HT neurons by 5-HT2 receptors 
 
Exogenous application of the 5-HT2A receptor antagonist, MDL 100907 and the 5-HT2C receptor 
antagonist, SB 242084 failed to attenuate the firing of DRN 5-HT neurons. This suggests that 
there is no 5-HT2A or 5-HT2C tonic conductance in 5-HT DRN neurons recorded in acute mouse 
brain slices. This observation is consistent with a previous study which performed whole-cell 
recordings from 5-HT neurons in rat brain slices (Liu et al., 2000). These authors failed to 
demonstrate any effect of MDL 100907 and SB 242084 when these antagonists we applied in 
the absence of agonist. In the results presented here, pre-application of each antagonist failed 
to attenuate the 5-HT-induced inhibition. This is at odds with the study conducted on rat brain 
slices where they demonstrated that each antagonist was able to significantly reduce the 5-HT 
response. The authors did note that applying both antagonists (in either order) produced a 
larger attenuation of the 5-HT response. It is therefore possible that combining both 
antagonists here could have produced an attenuation of the 5-HT response. However it is also 
possible that the limited number of neurons recorded here (n = 3 for each antagonist 
treatment) were not under regulatory control by 5-HT2 receptors.  
Application of the mixed 5-HT2A/2c agonist, DOI produced a significant inhibition of firing in 5-
HT DRN neurons. The DOI-induced inhibition reported here is consistent with previous studies 
performed in anaesthetised rats. Intra-raphe (Garratt et al., 1991) or systemic administration 
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(Boothman et al., 2003; Wright et al., 1990) of DOI produced a marked reduction in the firing 
of DRN 5-HT neurons. While not investigated here, a previous study demonstrated that the 
DOI-induced inhibition of DRN 5-HT neurons could be blocked by pre-treatment with ritanserin 
(5-HT2 receptor antagonist) or MDL 100907 (Boothman et al., 2003). It would therefore be 
pertinent in future studies to investigate which receptors were responsible for the DOI-
induced inhibition demonstrated in acute mouse brain slices. To date no study has revealed 
whether 5-HT2A and 5-HT2C receptors are located on the same neuron or different neurons.     
 
Whole-cell voltage-clamp recordings from DRN 5-HT neurons revealed that bath application of 
DOI prolonged the decay kinetics of GABAergic sIPSCs and mIPSCs but failed to attenuate the 
frequency or amplitude of these synaptic events. The DOI-induced prolongation of decay 
kinetics could indicate that DOI is directly modulating the GABAA receptor, causing the channel 
to remain open for a significantly longer time. To date, there are no other reports of DOI 
modulating the GABAA receptor directly. A previous study conducted in rat brain slices 
observed that application of DOI caused an increase in the amplitude and frequency of 
GABAergic IPSCs, an effect which was blocked by application of TTX, bicuculline and selective 
5-HT2 receptor antagonists (Liu et al., 2000). These results indicate that DOI is activating pre-
synaptic 5-HT2 receptors located on GABAergic neurons to produce its effect. This pre-synaptic 
action of DOI at 5-HT2 receptors located on GABAergic neurons has been demonstrated 
elsewhere in the brain including the hippocampus (Shen & Andrade, 1998) and midbrain 
periaqueductal grey (Jeong et al., 2013). Another explanation for effect of DOI observed here 
could be that DOI activated 5-HT2 receptors leading to increased intracellular second 
messenger systems which in turn modulated GABAA receptors. Alternatively, DOI could have 
attenuated GABA reuptake from the synapse. Neither of these effects has been demonstrated 
previously. While it is possible that the DOI effects observed here are real there are a number 
of considerations which much be discussed. Firstly these results are preliminary; the number 
of experiments reported here was low (n =5), to be confident in the observed effects more 
experiments would need to be performed. Secondly recovery from DOI was not investigated; 
this could be explored by post-application of a 5-HT2 antagonist or by washout of DOI. Lastly 
all of the experiments reported here were performed from the same vial of DOI powder, it is 
possible that there was contamination and hence using a new batch of drug would be 
important. One final point to note is that while the data reported here were not consistent 
with that reported previously, none of these authors investigated whether DOI altered the 
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decay kinetics of the GABAergic IPSCs (personal communication). It therefore remains to be 
seen whether DOI acts at both 5-HT2 receptors and GABAA receptors. 
 
3.5.3 Regulation of putative 5-HT neurons by orexin 
 
Extracellular single-unit recordings revealed that the bath application of orexin-A to DRN 5-HT 
neurons produced a significant increase in the firing frequency of all neurons tested. This is 
comparable to a previous study which applied orexin-A to 5-HT neurons in rat brain slices 
(Brown et al., 2002). These authors demonstrated that orexin-A had an excitatory effect on 
DRN 5-HT neurons and that this orexin-induced excitation could be occluded by pre-
application of phenylephrine. Whole-cell voltage-clamp recordings revealed that orexin-A 
produced a large, noisy inward current in DRN 5-HT neurons which could be blocked by the 
application of the mixed OX1/OX2 receptor antagonist, almorexant. This demonstration of a 
large, noisy inward current induced by orexin is in keeping with previous studies in mice 
(Kohlmeirer et al., 2008) and rats (Brown et al., 2002). These previous studies also 
demonstrated that application of orexin-A caused a significant depolarisation of DRN 5-HT 
neurons and was most likely due to the involvement of a non-selective cationic channel, 
possibly the canonical form of the transient receptor potential channel (TRPC). The authors 
suggested the TRPC was responsible based on the following observations: orexin-induced 
currents reversed in a Ca2+-free medium at -23mV consistent with a mixed cation channel 
(Brown et al., 2002), TRPC I-VII from classic, non-selective cation channels, TRPC mediate 
cation currents activated by Gq receptors (Kohlmeirer et al., 2008) and the expression of TRPCs 
was confirmed in the DRN 5-HT neurons that also co-express orexin receptors (Sergeeva et al., 
2003). To date, there are no pharmacological agents that can selectively inhibit the different 
TRPCs therefore their role mediated orexin effects in the DRN remains to be unequivocally 
shown.  Interestingly, the excitatory effect of orexin in the DRN has been previously shown to 
translate into increased 5-HT release in vivo (Tao et al., 2006) and infusion of orexin-A into the 
DRN of freely moving rats was shown to cause a dose-dependent increase in 5-HT release.  
 
Application of almorexant to 5-HT neurons under voltage-clamp conditions failed to alter the 
holding current of any neuron tested. The pre-application of almorexant was able to prevent 
the orexin-induced inward current. This preliminary data suggests that there is no orexin tone 
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present in DRN 5-HT neurons in vitro. No study has explored what effect intra-raphe 
administration of almorexant would have on 5-HT neurons. One would expect almorexant to 
have a depressant effect on DRN 5-HT neuronal firing in vivo. The magnitude of the effect 
would most likely depend on the circadian time point at which almorexant was administered 
as both orexin and serotonin neurons are known to fire faster during wakefulness and slower 
during sleep (Takahashi et al., 2008; Sakai, 2011). Dual orexin antagonists are currently being 
explored as novel sleep therapeutics. Pre-clinical data and clinical trials have demonstrated 
that dual orexin antagonists are able to increase NREM and REM sleep in animals and humans, 
without producing next day sedation or withdrawal. Almorexant has been shown to affect 
sleep-architecture in a dose-dependent manner, increasing both NREM and REM sleep, with 
higher doses decreasing the latency to REM sleep (Hoever et al., 2012a, b). Suvorexant has 
been shown to improve sleep efficiency and sleep latency in primary insomniacs (Herring et 
al., 2012). Merck is currently seeking FDA approval for the authorisation of suvorexant as a 
sleep aid. Given the profound effect of orexin on 5-HT neurons it is more than likely these 
drugs produce part of their observed effect by reducing the output of DRN 5-HT neurons.  
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Chapter 4: 
Histaminergic regulation of dorsal raphe neurons 
in vitro 
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4.1 Introduction 
 
It is currently thought that our state of wakefulness results from the concerted action of 
multiple transmitter systems found within the brain. Electrophysiological, neuropharmacogical 
and genetic approaches have revealed that serotonin neurons within the DRN function to 
promote wakefulness. While considerable progress has been made in elucidating the 
mechanisms by which serotonin neurons are regulated locally within the DRN much less is 
known about how other wake promoting neurons in the brain regulate serotonin neurons. The 
sleep-promoting effect of classical antihistamines which target the H1 receptor subtype 
(Hindmarch and Shamsi 1999) and the demonstration that these receptor subtypes are found 
in the DRN (Barbara et al., 2002), suggest a potential important role for DRN H1 receptors in 
the regulation of the sleep-wake cycle. This chapter focusses on the characterization of 
histamine actions upon serotonin neurons within the DRN.  
 
4.2 Histamine increases the firing rate of putative 5-HT neurons  
 
Using the extracellular single-unit recording technique, putative 5-HT neurons were tested 
with 10 µM histamine (Figure 4.1). A representative recording from a putative 5-HT neuron is 
illustrated in Fig 4.1.A. Bath application of histamine to the slice caused a large increase in the 
firing frequency of the cell. After a stable plateau was reached histamine was washed out and 
the firing frequency returned to control (pre-histamine) levels. When the control firing 
frequency is compared with the firing frequency in the presence of histamine we can see 
clearly that in every cell tested histamine causes a significant excitation (Fig 4.1.B). When 
expressed as a percentage of control it can be seen that histamine causes a significant 
excitation (340 ± 104%, p < 0.05 , paired Student’s t-test) of cell firing (Fig 4.1C). Using the cell-
attached voltage-clamp technique, putative 5-HT neurons were tested with 10 µM histamine 
(Figure 4.2). A representative recording from a putative 5-HT neuron is illustrated in Fig 4.2A. 
Similar to the single-unit recordings, bath application of histamine to the slice caused an 
increase in the firing frequency of the cell. When the control firing frequency is compared to 
firing frequency in the presence of histamine we again see that in every cell tested histamine 
caused a significant excitation (Fig. 4.2.B). When expressed as a percentage of  
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Figure 4.1. Histamine increases the firing of putative 5-HT neurons I. (A) A representative 
extracellular single-unit recording of the firing frequency (20s bins) from a spontaneously firing 
neuron in the presence of 10µM histamine. (B) Firing frequency of individual putative 5-HT 
neurons (open circles) before (control ) and after the application of histamine (10µM). The 
average firing frequency in control and in the presence of histamine is shown by the closed 
circles (mean ± SEM). (C) Bar graph showing the average effect of histamine when applied to 
spontaneously firing 5-HT neurons (n = 7). Effect is displayed as the mean percentage of 
control firing frequency ± SEM. * p < 0.05, *** p < 0.001, paired Student’s t-test. 
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Figure 4.2. Histamine increases the firing of putative 5-HT neurons II.  (A) A representative 
cell-attached recording of the firing frequency (20s bins) from a spontaneously firing neuron in 
the presence of 10µM histamine. (B) Firing frequency of individual putative 5-HT neurons 
(open circles) before (control ) and after the application of histamine (10µM). The average 
firing frequency in control and in the presence of histamine is shown by the closed circles 
(mean ± SEM). (C) Bar graph showing the average effect of histamine when applied to 
spontaneously firing 5-HT neurons. Effect is displayed as the mean percentage of control firing 
frequency ± SEM. * p < 0.05, *** p < 0.001, paired Student’s t-test. 
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control it can be seen that histamine caused a significant excitation (320%, p < 0.05, paired 
Student’s t-test) of cell firing (Fig 4.2.C).    
 
4.3 Histamine depolarises putative 5-HT neurons and increases their excitability 
 
The whole-cell current-clamp technique was utilised to measure the membrane potential and 
input-output curve of putative 5-HT neurons in the absence and presence of bath applied 
histamine (10µM). In 2 cells the mean resting membrane potential was calculated to be -61mV      
(-56mV and -63mV). The bath application of histamine caused an average depolarisation of 
+7.8mV (+6mV and +10mV) and caused action potential firing (Fig.4.3.A). The effect of the 
bath application of histamine on the input-output relationship of these neurons was also 
investigated. A stimulus protocol was applied whereby a group of current steps (-40 to 
+120pA, 20pA increments, 400ms duration) were injected into the neuron three times per 
experimental condition and the resulting number of action potentials per step was determined 
(see 2.6.5). In both cells histamine shifted the input-output curve to the left i.e. increased cell 
excitability (Fig.4.3.B).  
 
4.4 Histamine produces a large inward current in putative 5-HT neurons 
 
In order to further investigate the role of histamine in the DRN I utilised the whole-cell voltage-
clamp recording technique. Experiments were performed at a holding potential of -60mV with 
equal intracellular and extracellular chloride (see section 2.6.2). A representative voltage-
clamp recording from a putative 5-HT neuron is illustrated in Fig 4.4.A. In this recording the 
bath application of 10µM histamine produced a large inward current which was associated 
with an increase in the baseline noise (RMS). A second representative voltage-camp recording 
is illustrated in Fig. 4.4.B. In this recording 300µM histamine was focally applied to the slice 
and was seen to cause a large inward current which was associated with an increase in 
baseline noise. In 95% (19 out of 20) of neurons the bath application of histamine caused an 
inward current with a mean of   -36 ± 4pA (p < 0.001, paired Student’s t-test) and an increase 
in RMS with a mean of 3 ± 0.5pA (p < 0.001, paired Student’s t-test). In 90% (49 out of 54) of 
neurons the focal application of histamine produced an inward current with a mean of 17 ±  
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Figure 4.3.A  Histamine depolarises putative 5-HT neurons. A representative current-clamp 
recording in which bath application of histamine (10µM) caused a depolarisation of the cell 
and initiation of action potential firing.  
 
 
 
 
 
 
 
 
 
Figure 4.3.B. Histamine increases the excitability of putative 5-HT neurons. A plot of the 
current injected against the average action potential frequency of 2 responding neurons in 
each experimental condition.  Note the leftward shift of the trace with bath application of 
histamine (10µM). 
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1pA (p < 0.001, paired Student’s t- test) and an increase in RMS with a mean of 2 ± 0.1pA (p < 
0.001, paired Student’s t-test, Table 2.1). 
 
4.5 Histamine mediates its effect via the H1 receptor 
 
Having demonstrated that histamine has an excitatory effect on putative 5-HT neurons within 
the DRN it was next important to identify which histamine receptor was responsible. As H1, H2 
and H3 receptor subtypes are known to be located in the DRN (Barbara et al., 2002; Drutel et 
al., 2001) putative 5-HT neurons were challenged with specific antagonists of each receptor 
subtype. Representative voltage-clamp (VH = -60mV) recordings from putative 5-HT neurons 
are illustrated in Fig. 4.5. Histamine (300µM) was focally applied to each neuron (every 50s) 
and then a selective antagonist was bath applied. A total of 10 neurons were tested with the 
H1R antagonist, histabudifen. Although histabudifen (20µM) caused a significant inhibition of 
the histamine-induced inward current (p < 0.01, paired Student’s t-test) its effect was varied. 
In 2 cells there was complete inhibition of the histamine-induced current (Fig.4.5.A), in 7 cells 
there was partial inhibition and in 1 cell there was no effect. In order to assess whether the 
concentration of drug application was too low, three cells which were partially inhibited were 
challenged with a higher concentration of 60µM histabudifen. The higher concentration of 
histabudifen resulted in a complete inhibition of the histamine-induced current. It was thought 
that inconsistency in results obtained with histabudifen was due to a problem with the drug 
solubility and in light of this a second series of experiments was conducted with a different H1R 
antagonist, oxatomide. Application of 100nM oxatomide completely inhibited the histamine-
induced current in all cells tested (n = 4, data not shown). In order to investigate the role of H2 
and H3 receptors, selective antagonists of each receptor were applied. The H2 receptor 
antagonist, ranitidine (10µM) had no significant effect on the histamine-induced current (p = 
0.1, n= 6, paired Student’s test, Fig.4.5.B). Furthermore, the H3 receptor antagonist, 
thioperamide had no significant effect on the histamine-induced current when applied at a 
concentration of 1µM (p = 0.6, n = 5 paired Student’s t-test, Fig.4.5.C) or 10µM (p = 0.8, n = 3, 
paired Student’s t-test).  
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Figure 4.4.A The bath application of 10μM histamine to putative 5-HT neurons causes an 
inward current. A representative recording (VH = -60mV) from a 5-HT neuron illustrating the 
inward current induced by  bath application of 10μM histamine. The corresponding all points 
histogram and current shift is given to the right with the value of current shift.  
 
 
 
 
 
 
 
 
 
Figure 4.4.B. The focal application of 300μM histamine to putative 5-HT neurons causes an 
inward current. A representative recording (VH = -60mV) from a 5-HT neuron illustrating the 
inward current induced by repetitive focal application of 300μM histamine (6ms and 10psi). 
The value of current shift is given to the right.  
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Responding 
neurones
10μM histamine
(bath application)
300μM histamine
(focal application)
Mean Δ current  ± SEM
(range)
Mean Δ RMS  ± SEM
(range)
19/20 (95%)
-36 ± 4pA
(-12 to -77pA)
3 ± 0.5pA
(0 to 5.5pA)
49/54 (90%)
-17 ± 1pA
(-6 to -51pA)
2 ± 0.1pA
(1 to 4pA) 
***
***
***
***
 
 
 
 
 
 
 
Table 2.1. Bath and focal application of histamine causes an inward current associated with 
an increase in the baseline noise (RMS) in putative 5-HT neurons. *** p < 0.001, paired 
Student’s t-test.   
 
 
 
4.6 H1Rs are constitutively active in the DRN 
 
In vitro studies conducted over the last decade have revealed that H1Rs can be functionally 
active in the absence of bound agonist i.e. constitutively or spontaneously active (Bakker et al., 
2000; Leurs et al., 2002). The constitutive activity of a receptor can be revealed by the 
application of inverse agonists and neutral antagonists. Inverse agonists have negative efficacy 
(shifting the receptor equilibrium towards the inactive state) whereas neutral antagonists have 
zero efficacy (see section 1.2.2). Since the observation that H1 antagonists can have negative 
efficacy, many have been reclassified as inverse agonists, raising important questions 
regarding the therapeutic applications of such ligands (Monczor et al., 2013).  
 
Given the presence of functional H1Rs in my DRN slices I wanted to investigate whether these 
receptors were constitutively active. In voltage-clamp recordings of neurons expressing  
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Figure 4.5 Histamine mediates its effects via the H1 receptor. Representative recordings (VH = 
-60mV) from putative 5-HT neurons illustrating the focal application of 300µM histamine 
during control (left) and during bath application of selective histamine receptor antagonists 
(right). (A) Bath application of 20µM histabudifen (H1R antagonist) completely blocks the 
histamine-induced inward current.  (B) Bath application of 10µM ranitidine (H2R antagonist) 
has no effect on the histamine-induced current. (C) Bath application of 1µM thioperamide (H3R 
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antagonist) also has no effect on the histamine-induced current. Note that all antagonist 
concentrations were selected based on an extensive literature search. 
 
constitutively active H1Rs, the inverse agonist induced closure of these receptors would be 
revealed as a shift in the holding current. The presence of these receptors in the DRN was 
investigated by bath applying two structurally distinct H1 inverse agonists, mepyramine and 
dimethindene. These experiments were performed at a holding potential of -60mV with equal 
intracellular and extracellular chloride (see section 2.6.2). In the first series of experiments 
histamine (10μM) was bath applied to the slice followed by the bath application of 
mepyramine (300nM and 1μM). Bath application of histamine caused an average inward 
current of -38 ± 10pA, application of 300nM mepyramine caused an average outward current 
of 24 ± 7pA and application of 1μM mepyramine caused a further outward current shift of 18 ± 
4pA (n = 6). Taken as a whole, 300nM is able to partially inhibit the histamine-induced current 
but it appears that 1μM mepyramine is required to fully inhibit the histamine effect. Voltage-
clamp recordings from two putative 5-HT neurons illustrated in Fig.4.6 demonstrate the 
different responses to 300nM and 1μM mepyramine. In the first example 1μM mepyramine is 
required to completely inhibit the histamine-induced inward current (Fig.4.6 top) whereas in 
the second example 300nM causes complete inhibition and the subsequent application of 1μM 
mepyramine shifts the current further, beyond the control baseline (Fig.4.6 bottom). This shift 
in current above the control baseline suggested that there was a tonic histamine conductance 
present.  
 
In order to assess the tonic histamine conductance further I focally applied 300μM histamine 
and bath applied mepyramine (300nM or 1μM) or dimethindene (100nM). In 3 cells the bath 
application of 300nM mepyramine completely inhibited the histamine-induced current and 
caused an average shift in the baseline current of +32 ± 18pA (Fig.4.7). A further 6 cells were 
challenged with 1µM mepyramine and this resulted in the inhibition of the histamine-induced 
current and average shift in the baseline current of +24 ± 3pA (Table 2.2). Application of 
100nM dimethindene to 6 cells resulted in the inhibition of the histamine-induced current in 
every cell tested and an average shift in the baseline current of +28 ± 7pA in 5 of the cells 
tested (Table 2.2). Although this set of experiments strongly suggested the presence of a tonic 
H1R conductance it could be argued that the exogenous application of histamine could account  
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Figure 4.6. H1 receptors are responsible for the histamine-induced inward current recorded 
from putative 5-HT neurons. Representative recordings (VH = -60mV) from putative 5-HT 
neurons illustrating that the inward current  induced by 10µM histamine is reversed by 
application of mepyramine (300nM and 1µM). The corresponding all points histograms are 
given to the right with the value of current shift. Note that in the 5-HT neuron illustrated in the 
top trace 1µM mepyramine only returns the current to the baseline whereas in the 5-HT 
neuron in the bottom trace application of 1µM mepyramine reveals a tonic histamine 
conductance.  
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Figure 4.7. The bath application of 300nM mepyramine inhibits the histamine induced 
current and causes a shift in the holding current. A representative recording (VH = -60mV) 
from a 5-HT neuron illustrating the focal application of 300µM histamine and subsequent bath 
application of 300nM mepyramine. Mepyramine inhibits the histamine induced current and in 
addition causes a shift in the baseline current (+14pA). 
 
 
 
 
 
 
Table 2.2. Bath application of mepyramine and dimethendene causes a shift in the baseline 
current and a reduction in the baseline noise (RMS) in putative 5-HT neurons.  * p < 0.05 and 
*** p < 0.001, paired Student’s t-test.   
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Figure 4.8. Putative 5-HT neurons in the DRN exhibit a tonic conductance mediated by H1 
receptors. A representative recording (VH = -60mV) from a putative 5-HT neuron illustrating 
the shift current revealed by 1µM mepyramine. The corresponding all points histogram is 
shown to the right with the value of current shift.  
 
 
 
 
 
 
 
Table 2.3. A portion of putative 5-HT neurons exhibit a tonic conductance mediated by H1 
receptors. Application of 1µM mepyramine revealed 100% of neurons exhibited a tonic 
conductance with an average shift of 20 ± 4pA (mediated by H1 receptors). Application of 
300nM mepyramine revealed 62.5% of neurons exhibited a tonic conductance with an average 
shift of 25 ± 7pA whereas application of 100nM mepyramine revealed only 25% of neurons 
exhibit a tonic conductance. * p < 0.05 and *** p < 0.001, paired Student’s t-test.  
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for these observed effects. To further confirm that the measured conductance did not 
originate from exogenously applied histamine I bath applied mepyramine (100nM, 300nM or 
1µM) in absence of any exogenously applied histamine. A representative voltage-clamp 
recording is illustrated in Fig 4.8. The bath application of 300nM mepyramine caused a shift in 
the baseline current of +25pA. A comparison of all three concentrations of mepyramine is 
illustrated in Table 2.3. It can be seen that 300nM and 1µM cause a similar magnitude of 
current shift however 100nM was only able to causes a current shift in 1/5 neurons. This 
confirms that H1R are tonically active within the slice but it does address the origin of the tonic 
conductance i.e. whether it originates from constitutive activity or ambient levels of histamine. 
If ambient levels of histamine were responsible for the tonic conductance application of a 
neutral H1R antagonist would produce similar results to those seen with the inverse agonists. 
In 5 cells tested the bath application of the neutral H1R antagonist, oxatomide (100nM) caused 
no change in the holding current (Fig.4.9). Furthermore when mepyramine (1µM) was 
subsequently applied in the presence of oxatomide it was unable to produce any shift in the 
baseline current. These results indicate that H1Rs are constitutively (spontaneously) active on 
putative 5-HT neurons present within the DRN.  To the best of my knowledge this is the first 
demonstration of the constitutive activity of H1Rs in the DRN.  
 
 
 
 
 
 
 
Figure 4.9. Bath application of 100nM oxatomide blocks the effect of mepyramine. A 
representative recording (VH = -60mV) from a putative 5-HT neuron illustrating that the neutral 
antagonist oxatomide (100nM) has no effect on the baseline current and furthermore blocks 
the actions of mepyramine (1µM). The corresponding all points histogram is shown on the 
right: black (baseline), grey (oxatomide) and white (mepyramine).  
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4.7 H1Rs are located on putative 5-HT neurons 
 
H1Rs have been found postsynaptically in numerous regions throughout the brain and there is 
evidence to suggest they may present postsynaptically within the DRN (Brown et al., 2002). In 
order to confirm the postsynaptic location of H1Rs on putative neurons in the DRN I performed 
voltage-clamp recordings (VH = -60mV) from neurons in the DRN in the absence and presence 
of voltage-dependent Na+ channel blocker TTX. Bath application of 0.5µM TTX did not cause 
any change in the baseline current of neurons. In addition when histamine was bath applied in 
the presence of TTX it was still able to produce an inward current associated with an increase 
in the RMS (Fig.4.10). When the magnitude of the histamine-induced current is compared in 
the presence of TTX (n = 5) and absence of TTX (n = 19) there is no significant difference (Table 
2.4). This suggests that the current originated locally from the activation of H1Rs within the 
recorded cell. More evidence for the local activation of these receptors was provided when 
voltage-clamp recordings were performed with GDP-βS (a non-hydrolysable GDP analogue) 
substituted in the recording pipette. GDP-βS prevents G-protein coupled receptors from 
functioning correctly, as it was present within the recording pipette its action is limited to the 
neuron onto which it is patched. Under these recording conditions the focal application of 
histamine (300µM) failed to produced any change in the holding current (n = 8, Fig.4.11.A). 
Furthermore bath application of 1µM mepyramine failed to cause any change in the holding 
current (n = 4, Fig.4.11.B). These results demonstrate that H1Rs are located on putative 5-HT 
neurons and that these G protein coupled receptors require GTP to function correctly.   
 
4.8 H1R inhibition causes a decrease in the input resistance of putative 5-HT neurons 
 
In many neurons the activation of postsynaptic H1Rs have been shown to cause a 
depolarisation and/or an increase in firing frequency. Several different mechanisms are 
thought to underlie this excitability including the block of a leak K+ conductance (McCormick 
and Williamson, 1991; Reiner and Kamondi, 1994), activation of a TTX-insensitive Na+ current 
(Gorelova and Reiner, 1996) and the activation of Ca2+-activated cationic current (Smith and 
Armstrong, 1996). 
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Figure 4.10. Bath application 0.5µM TTX has no effect on the baseline current and has no 
effect on histamine-induced current. A representative recording (VH = -60mV) from a putative 
5-HT neuron illustrating that TTX (0.5µM) has no effect on the baseline current. Furthermore 
TTX has no effect on the histamine-induced current produced by the bath application of 
histamine (10µM). 
 
 
 
 
 
 
Table 2.4. Application of 0.5μM TTX has no effect on putative 5-HT neurons and does not 
attenuate the histamine-induce current or increase in RMS. Bath application of TTX did not 
produce any effect on the holding current or RMS in any cells tested. When we compare the 
bath application of histamine (10µM) in the presence of TTX and in the absence of TTX we can 
see that blocking Na+ dependent action potentials has no effect on the histamine-induced 
current.  Furthermore when the bath application of histamine in the presence of TTX is 
compared to a separate group of cells devoid of TTX we can see the values are almost 
identical.  * p < 0.05 and *** p < 0.001, paired Student’s t-test.  
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In 5-HT neurons in the DRN it is suggested that histamine activation of H1Rs leads to activation 
of a mixed cationic conductance (Brown et al., 2002).  To further elucidate the H1R mechanism 
within the DRN I performed whole-cell voltage-clamp recordings (VH = -60mV) and assessed 
the neuronal input resistance in the absence and presence of bath applied mepyramine (see 
section 2.6.5). Neurons exhibited a mean input resistance of 308 ± 11MΩ (n = 3) and the bath 
application of 1μM mepyramine decreased the neuronal input resistance in all cells tested to 
210 ± 14MΩ (see Fig.4.12). Given the decrease in input resistance observed with mepyramine 
it was thought that de-activation of H1Rs may be linked to a leak potassium conductance. 
Preliminary voltage-ramp experiments were conducted in order to obtain an I-V plot, which I 
assumed would cross at the potassium equilibrium potential. Unfortunately technical 
problems prevented the completion of this set of data. 
 
 
 
 
 
 
 
 
 
 
Figure 4.11. Inclusion of GDP-βS to the recording pipette prevents the histamine-induced 
current and tonic histamine conductance. A representative recording (VH = 60mV) from a 
putative 5-HT neuron illustrating that when GDP-βS is included in the recording pipette 
histamine fails to produce a shift in the holding current and furthermore mepyramine (1µM) 
no longer has any effect on the baseline current 
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Figure 4.12.  Bath application of mepyramine decreases the input resistance of putative 5-HT 
neurons. Measurement of input resistance in voltage-clamp mode before and after 1µM 
mepyramine application. Top: current shift of a 5-HT neuron induced by a hyperpolarising 
voltage step (-4mV). Not that the current shift is larger in the presence of mepyramine  
indicative of a decrease of input resistance (V = IR). Bottom: Bar graph illustrating the average 
input resistance in the absence and presence of mepyramine (n = 3). p < 0.05 paired Student’s 
t-test.   
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4.9 Discussion 
 
4.9.1 Histamine excites putative 5-HT neurons in the DRN 
 
Extracellular single-unit recordings and cell-attached performed from putative 5-HT neurons in 
the DRN revealed that all of the neurons tested were excited by histamine. The histamine-
induced excitation was reversed upon washout confirming that the observed effect was not an 
erroneous response. This reversible excitation is consistent with previous studies performed in 
vitro in rat brain slices. The first study demonstrated that histamine (50µM) produced a rapid 
excitation in 67% of neurons tested (Brown et al., 2002) and the second study demonstrated 
that histamine (3-30µM) produced an excitation in 84% of neurons in a concentration-
dependent manner (Bárbara et al., 2002). The discrepancy between the percentages of 
responding neurons could be due to a species difference in the expression of histamine 
receptors. Hence, H1 receptor expression might be lower in the rat DRN. Currently no study 
has been performed to map the expression pattern of histamine receptors in the DRN of either 
species, therefore this is just conjecture at this time.  
 
Both bath application and local (spritz) application of histamine produced an inward current 
associated with an increase in baseline noise. These results are indicative of histamine causing 
receptors on the cell surface to open allowing ions to flow across the membrane. These data 
are also comparable to those obtained from 5-HT neurons in the rat DRN. The authors 
demonstrated that application of histamine (50µM) caused an inward current (-37 ± 9pA) 
associated with an increase in current noise and furthermore that histamine depolarised 5-HT 
neurons (Brown et al., 2002).  
 
4.9.2 Histamine mediates it effect via the H1 receptor 
 
Whole-cell voltage-clamp experiments were performed in order to investigate which histamine 
receptor (H1, H2 or H3) was responsible for the observed excitability in DRN 5-HT neurons. Bath 
application of two structurally distinct neutral H1 receptor antagonists, histabudifen and 
oxatomide, inhibited the histamine-induced inward current. Whereas bath application of the 
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H2 antagonist, ranitidine and H3 antagonist, thioperamide failed to significantly attenuate the 
histamine response. These data are in keeping with previous work which demonstrated that 
the histamine-induced excitation of rat DRN 5-HT neurons could be inhibited by blocking H1 
receptors (Brown et al., 2002) whereas blocking H2 receptors had no effect (Bárbara et al., 
2002). However a very early study did demonstrate a role for H2 receptors in the DRN. In this 
study microionophoretic application of histamine to DRN of aneasthetised rats produced a 
depression of cell firing in 240 serotonergic neurons tested (Lakoski & Aghajanian, 1983). This 
histamine-induced depression was shown to be attenuated by the H2 antagonist, ranitidine but 
remained unaffected by inhibition of H1 receptors. A follow up study also demonstrated that 
this histamine-induced depression could be attenuated by a second H2 antagonist, cimetidine 
(Lakoski & Aghajanian, 1984). The authors demonstrated that the depression in firing caused 
by histamine could be antagonised by bicuculline and picrotoxin, suggesting a role for GABAA 
receptors in the observed histamine effect. It is possible that this observation could be species 
specific, although if this was the case it would be reasonable to assume that one or both of the 
more recent studies conducted in rats would have observed this effect. Neither reported any 
depressant effect. It is therefore possible that DRN 5-HT neurons are under regulatory control 
by both histamine receptors subtypes. H1 receptors could directly activate 5-HT neurons 
through a postsynaptic mechanism whereas H2 receptors could inhibit 5-HT neurons through 
an indirect mechanism involving GABAgergic neurons.  As noted above, no study has 
investigated the expression pattern of histamine receptors therefore it remains to be 
elucidated whether H2 receptors are located on GABAergic interneurons or afferents present 
in the DRN.  
 
4.9.3 H1 receptors are constitutively active in the DRN 
 
Whole-cell voltage-clamp experiments were performed in order to investigate whether H1 
receptors in the DRN were constitutively (spontaneously) active. Bath application of two 
structurally distinct inverse agonists, mepyramine and dimethindene, not only inhibited the 
histamine-induced inward current observed in 5-HT neurons but also produced a shift in 
current beyond the baseline. Application of oxatomide to the slice failed to produce any 
change in the holding current and furthermore, inhibited the current shift produced by 
mepyramine. Taken together, these data indicate that H1 receptors are constitutively active in 
the mouse DRN. Functional assays have revealed that H1 receptors are constitutively active in 
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vitro (Bakker et al., 2000, 2001) however this is the first demonstration of constitutive activity 
in the DRN. This demonstration raises important questions as to the physiological role of 
constitutive H1 receptor signalling in the DRN especially given the reclassification of a number 
of H1 receptor antagonists as inverse agonists. This constitutive activity could represent a rate-
limiting mechanism which would allow the histaminergic system to regulate DR 5-HT neurons 
irrespective of the level of histamine in the nucleus. It will be important to confirm the results 
presented here using an alternative method. Confirmation of constitutive H1 receptor activity 
could be demonstrated by first depleting histamine from the slice (using a histidine 
decarboxylase inhibitor e.g. α-fluromethylhistidine) and then applying an inverse agonist.  
 
The ability of GPCRs to achieve a constitutively (or spontaneously) active conformation was 
first demonstrated in delta opioid receptors (Costa & Hertz, 1989). Since this seminal study the 
constitutive activation of GPCRs is now well established, with recent reports suggesting that 
80% of the classical GPCR antagonists have been reclassified as inverse agonists (Bond & 
Ijzerman, 2006) and that nearly all GPCRs display some constitutive activity (Khilnani & 
Khilnani, 2011). The clinical significance of constitutive receptor activity has been 
demonstrated in a number of diseases in which constitutively activated mutants exist. 
Mutations can lead to receptor under-activity (e.g. diabetes insipidus, retinitis pigmentosa and 
congenital night blindness), receptor over-activity (e.g. Leydig cell tumour and familial 
hypocalciuria) or alterations of coupling efficiency (e.g. allelic variants of human β-
adrenoreceptors) (Spiegel & Weinstein, 2004). Inverse agonism at H1 receptors may be a key 
component of the anti-allergic action of clinically used antihistamines (Khilnani & Khilnani, 
2011). Cardiotoxic and anti-inflammatory effects of particular H1 antihistamines are attributed 
to inverse agonism (Fitzimmons  et al., 2004)  Furthermore given the reciprocal regulation 
between the DRN and TMN during wakefulness it is more than likely that constitutive receptor 
activity would have a modulatory role during the emergence from waking. Most of the 
clinically available H1 antihistamines are now know to be inverse agonists. Unfortunately no 
study to date has compared the effect of a H1 inverse agonist and H1 neutral antagonists on 
measured sleep parameters.  
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4.9.4 H1 receptors are located on putative 5-HT neurons 
 
After demonstrating the functional presence of constitutive H1 receptor activity in the DRN the 
focus of the investigation turned to understanding where these receptors were located. 
Histamine was bath applied to cells under voltage-clamp. TTX was pre-applied to neurons but 
failed to alter the holding current or baseline noise, furthermore it failed to alter the 
histamine-induced current when these neurons were compared to TTX-free neurons. This 
suggested that histamine was not dependent on impulse flow from pre-synaptic neurons to 
exert its effect. In order to confirm that histamine was acting postsynaptically, GDP-βS was 
included in the intracellular solution. When GPCRs were blocked in the patched neuron 
histamine failed to produce any effect. Taken together these strongly suggest that H1 receptors 
are located postsynaptically on serotonergic neurons i.e. the recorded neuron. This is the first 
compelling evidence that histamine receptors are located directly on 5-HT neurons in the DRN. 
A previous study inferred that H1 receptors are located postsynaptically from electrophysiology 
data which compared the effects of histamine, phenylephrine and orexin in the DRN (Brown et 
al., 2002). As described above it will be important to map the expression of histamine 
receptors further in the DRN to explore whether these neurons are expressed on 5-HT and 
non-5-HT neurons (e.g. GABAergic neurons). Histamine receptor expression could be mapped 
in the DRN using immunohistochemistry (with selective antibodies for each histamine receptor 
subtype) or by employing reverse-transcription polymerase chain reaction techniques to 5-HT 
cellular contents post-patching. Furthermore, it will be useful to know what effect, if any, 
histamine receptors have on non-serotonergic neurons in the DRN. Mice expressing green 
fluorescence protein specifically in GABA neurons (GAD67 strain of mice) are available and 
would quite easily enable researchers to assess what physiological role histamine has on these 
neurons.  
 
4.9.5 Inhibition of H1 receptors leads to a decrease in input resistance 
 
Whole-cell voltage-clamp recordings were performed in order to elucidate ionic mechanisms 
by which histamine produced an increase in the excitability of DRN 5-HT neurons. Preliminary 
data show that application of mepyramine decreased the input resistance of 5-HT neurons, 
suggesting that the activation of a leak potassium conductance could be responsible. This data 
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should be interpreted with caution given the low number of experiments performed. In the 
future, voltage-clamp studies could be performed in order to assess whether voltage-ramps 
cross at the equilibrium potential. Furthermore, experiments should be performed to confirm 
that histamine produces the opposite effect to mepyramine i.e. decreases the input resistance 
of serotonergic cells.   
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Chapter 5: 
Histaminergic regulation of dorsal raphe neurons 
in vivo 
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5.1 Introduction 
 
As demonstrated by the experiments described in the previous section and in agreement with 
previous reports, histamine acts via the H1 receptor to excite/depolarise presumed 5-HT 
neurons in the DRN (Barbara et al., 2002; Brown et al., 2002). In addition these experiments 
have suggested for the first time that H1 receptors can be constitutively active in the DRN. To 
investigate the physiological role of H1 receptors in the DRN further it was imperative that 
experiments were performed in vivo. Two approaches were taken; firstly single-unit 
recordings were made from DRN of anesthetised, head-restrained rats to assess if these 
receptors were functionally active and secondly EEG recordings were performed on freely 
moving animals to investigate the effect of H1 receptor blockade on a number of sleep-wake 
parameters.   
 
5.2 Mepyramine decreases the firing of putative 5-HT neurons in the DRN 
 
Extracellular single-unit recordings were made from putative 5-HT neurons in the DRN of rats 
under urethane anaesthesia. A representative action potential can be seen in Figure 5.1. The 
majority of neurons (10/11) fired tri-phasic (positive-negative-positive), broad action 
potentials (3.2 ± 0.1ms, Fig.5.1.A1) in a highly regular pattering (CV of 0.4 ± 0.1, Fig.5.1.A2) and 
with low frequency (2.2 ± 0.4Hz, Fig.5.1.A3). One neuron fired bi-phasic (positive-negative), 
broad action potentials, a comparison of these neurons is illustrated in Figure.5.1.B. The 
observation of bi-phasic and tri-phasic, broad action potentials made in this study is consistent 
with previous recordings from 5-HT neurons in the DRN of rats under urethane anaesthesia 
(Allers and Sharp, 2003).  
 
The effect of intravenous (i.v.) administration of mepyramine was tested in 13 cells (from 13 
animals). A dose of 10mg/kg was selected based on previous studies however this proved fatal 
(n = 1). The dose was reduced to 3mg/kg but unfortunately this also proved fatal in some 
animals (1/3) therefore the non-lethal dose of 1mg/kg was selected for the study. A 
representative recording is illustrated in Figure.5.2. After a stable baseline (20 minutes) each 
animal received a vehicle treatment of 1ml/kg 0.9% NaCl (i.v.) and drug treatment of 1mg/kg 
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mepyramine (i.v.). It can be seen that the vehicle treatment does not alter the firing frequency 
of the neuron but subsequent administration of 1mg/kg mepyramine produces a rapid 
decrease in firing (Fig.5.2.A). When the firing frequency during vehicle treatment is compared 
with firing frequency during mepyramine treatment we can see there is a significant decrease 
across all cells tested (Fig.5.2.B). When expressed as a percentage of control it can be seen 
that 1mg/kg mepyramine caused a significant inhibition (56%, p < 0.05, paired Student’s t-test) 
of cell firing across all 8 cells tested (Fig.5.2.C). In one instance the administration of 1mg/kg 
mepyramine produced an increase in the firing of the recorded neuron (25%, data not shown).                
 
5.3 Mepyramine increases NREM sleep  
 
Although the sedating properties of H1 receptor inverse agonists/antagonists (antihistamines) 
are well known and drugs which enhance sleep by blocking H1 receptors have been available 
over the counter for many years the precise mechanisms of action by which these agents 
cause drowsiness is unknown. I therefore performed EEG recording on freely moving rats in 
order to investigate the behavioural effect of mepyramine. Rats were intravenously 
administered 1mg/kg mepyramine or 1ml/kg vehicle (20% HBCD) at circadian time 5 (i.e. 5 
hours after lights on). Measurements of sleep-wake characteristics were performed for 24 
hours before (baseline) and 30 hours after drug treatment (see section 2.8.4). Animals were 
undisturbed for the duration of the study with the exception of 30mins at the time of dosing.  
 
Intravenous administration of 1mg/kg mepyramine produced a significant decrease in the 
percentage of time spent awake and concurrently produced an increase in the percentage of 
NREM sleep in the first two hours after dosing (p < 0.025, ANCOVA, Fig.5.3). The latency to 60 
seconds of continuous sleep was reduced from 36.9 ± 4.1 mins to 25.9 ± 2.8 mins after 
administration (p < 0.025 ANCOVA). The average length of sleep bout was also significantly 
increased in the first two hours after dosing (p < 0.025, ANCOVA, Fig.5.4). Mepyramine 
significantly increased the accumulated amount of NREM sleep after dosing (p < 0.025, 
ANCOVA, Figure 5.5) however mepyramine failed to have a significant effect on REM sleep at 
any time point (data not shown). In the first 7 hours after dosing (CT-5 to CT-12) mepyramine 
significantly increased the time animals were in NREM from 218.8 ± 4.4 minutes to 244.2 ± 4.4 
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minutes (p < 0.001, ANCOVA). It should also be noted that administration of mepyramine led 
to a decrease in the body temperature in the first hour after dosing (Fig.5.6). 
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Figure 5.1. Extracellular single-unit recordings of 5-HT neurons in the DRN. (A1) A 
representative tri-phasic, broad-width action potential (spike) recorded from the DRN. (A2) A 
representative interevent-interval histogram (in 25ms bins) indicating a very regular firing 
pattern (CV = 0.3). (A3) A representative 10 second section of the spike train. (B) A table 
summarising the electrophysiological properties analysed to establish 5-HT neuronal identity. 
Values are displayed as the average ± SEM. Values in parentheses represent the range of 
values. 
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Figure 5.2.  Mepyramine decreases the firing of neurons in the DRN. (A) A representative 
recording of the firing frequency (20s bins) from a spontaneously firing neuron in the presence 
of saline and 1mg/kg mepyramine. (B) Firing frequency of individual neurons (open circles) 
before (vehicle) and after the application of mepyramine (1mg/kg). The average firing 
frequency in vehicle and in the presence of histamine is shown by the closed circles (mean ± 
SEM). (C) Bar graph showing the average effect of histamine when applied to spontaneously 
firing neurons (n = 8). Effect is displayed as the mean percentage of control firing ± SEM. * p < 
0.05, paired Student’s t-test 
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Figure 5.3. Mepyramine produces a decrease in the amount of wake time with a concurrent 
increase in NREM sleep after dosing. A plot of the percentage of wake (top) and NREM sleep 
(bottom) per hour illustrating rats  administered intravenously with vehicle (1ml/kg 2-HBCD, 
grey, n = 10) and mepyramine (1mg/kg mepyramine, red, n = 10) at CT-5 (red triangle). Hourly 
values are represented as mean ± SEM.* p < 0.025, ANCOVA.   
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Figure 5.4. Mepyramine produces an acute increase in the aligned sleep bout. A plot 
illustrating the average duration of sleep bout in rats administered intravenously with vehicle 
(1ml/kg 2-HBCD, grey, n = 10) and mepyramine (1mg/kg mepyramine, red, n = 10) at CT-5 (red 
triangle). Hourly values are represented as mean ± SEM.* p < 0.025, ANCOVA. 
 
 
 
 
 
 
 
 
 
 
Figure 5.5. Mepyramine increases the amount of NREM sleep. A plot illustrating the 
accumulation of NREM sleep after rats were administered intravenously with vehicle (1ml/kg 
2-HBCD, grey, n = 10) and mepyramine (1mg/kg mepyramine, red, n = 10). Hourly values are 
represented as mean ± SEM.* p < 0.025, ANCOVA.   
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Figure 5.6. Mepyramine decreases body temperature. A plot illustrating the temperature 
deviation from the baseline mean. In rats administered intravenously with vehicle (1ml/kg 2-
HBCD, grey, n = 10) and mepyramine (1mg/kg mepyramine, red, n = 10) at CT-5 (red triangle).  
Hourly values are represented as mean ± SEM.* p < 0.025, ANCOVA.   
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5.4 Discussion 
 
5.4.1 Mepyramine decreases the firing of putative 5-HT neurons in the DRN 
 
Intravenous administration of 1mg/kg mepyramine to rats under urethane anaesthesia 
produced a decrease in the firing of putative 5-HT neurons in the DRN. This result is consistent 
with data from a previous study which demonstrate that microiontophoretic application of 
mepyramine into the DRN of anesthetised rats had a depressant effect on 5-HT neurons 
(Lakoski and Aghajanian, 1983). In addition the results presented here are in keeping with a 
previous study in cats which demonstrated that infusion of mepyramine into the DRN 
suppressed the discharge of 5-HT neurons during wakefulness and slow wave sleep (Sakai and 
Crochet, 2000). When comparing the results from previous studies with the results presented 
here it is important to consider that mepyramine was administered by different routes i.e. 
locally into the DRN versus systemically. Therefore while previous studies could conclude that 
mepyramine was acting at H1 receptors located within the DRN to depress 5-HT neurons, this 
same conclusion cannot be made based on the results presented in this section alone. If the 
results presented in vivo (Chapter 5) are combined with those obtained in vitro (Chapter 4) it 
could be concluded that mepyramine administered systemically acts predominantly via H1 
receptors in the DRN to produce its depressant effect, however the possibility that 
mepyramine could be acting at H1 receptors located in other brain regions that impinge on the 
DRN cannot be ruled out.  
 
In the present study the magnitude of mepyramine inhibition was highly variable, ranging 
from partial to full inhibition (6 - 100%). As the recordings were performed on rats under 
urethane anaesthesia it is conceivable that the level of urethane in the brain could affect the 
mepyramine response. The level of mepyramine in the brain will also be dependent on the 
pharmacokinetic profile of the drug and therefore will vary between animals, however the 
rapidity of the response suggests a very fast transport of drug into the brain following 
intravenous administration, and pharmacokinetic studies support high levels of drug measured 
in the brain following 1mg/kg i.v. (personal communication, Lilly). It has recently been shown 
in vitro that urethane can attenuate the response of 5-HT neurons in the DRN to various 
modulatory agents (McCardle and Gartside, 2012). Moreover the authors demonstrated that 
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the concentration of mepyramine could affect the magnitude of the attenuation in certain 
incidences. It would be pertinent in future studies to monitor the brain levels of urethane in 
order to extrapolate the affect that this has on the magnitude of mepyramine inhibition. While 
1mg/kg mepyramine significantly inhibited the firing of the majority of neurons (6/8) it failed 
to have a significant effect on some (2/8). This is in keeping with the in vitro data which 
demonstrated the mepyramine had an inhibitory effect on most but not all of the neurons 
tested (section 4.6). It is most likely that neurons which failed to respond to mepyramine did 
not express H1 receptors. These neurons may represent a subset population present in the 
DRN which are not regulated by histamine (at least via the H1 receptor subtype). Similar 
findings were demonstrated in recordings made from the cat (Sakai and Crochet, 2000). In this 
study the authors went on to show that neurons which failed to respond to histamine and 
mepyramine were attenuated by the α1-adrenoreceptor agonist, phenylephrine. The authors 
concluded that noradrenergic and histaminergic inputs target different populations of 5-HT 
neurons in the DRN. 
 
It should also be noted here that in one neuron mepyramine produced a significant excitation 
of the baseline firing. This excitation was not seen in the in vitro data and likewise was not 
reported in any other study. While it is possible that this is an erroneous result it could also 
represent the presence of an indirect inhibitory effect of histamine in the DRN, possibly via 
GABAergic interneurons. However, it is important to note that that no histology was 
performed to confirm electrode placement in the DRN and no immunohistochemistry was 
carried out to confirm the neuronal identity of recorded neurons. In this study, putative 
serotonin neurons were selected based on their action potential shape (wide, bi- or tri-phasic 
waveform) and firing properties (slow, rhythmic discharge rates). As these characteristics do 
not guarantee 5-HT neuronal identity, it is possible that the neuron which was excited by 
mepyramine represents the response of a non-serotonergic neuron. 
 
Taken together, these in vivo single-unit results demonstrate the functional activity of H1 
receptors in the DRN of rats.  Future studies should investigate whether these receptors are 
constitutively active in the whole brain. This could be achieved by utilising neutral antagonists 
of the H1 receptor e.g. oxatomide and histabudifen. These ligands have zero efficacy (whereas 
inverse agonists with negative efficacy) therefore if no effect was observed after their 
124 
 
 
administration one could propose that these receptors are constitutively active in vivo. These 
results demonstrate the heterogeneity of regulation in the DRN and exemplify just how 
complex the neuronal networks which control the sleep-wake cycle are. Lastly, these data 
highlight the need for post-hoc identification of the recording site (via staining or 
chemical/electrical lesioning) or better yet, the post-hoc identification of the neuron (using 
juxtacellular labelling). 
 
5.4.2 Mepyramine increases NREM sleep 
 
Intravenous administration of 1mg/kg mepyramine to rats produced a significant decrease in 
wakefulness and increase in NREM sleep in the two hours following dosing. In addition the 
length of the sleep bout was also significantly increased, however, no significant attenuation 
of REM sleep was observed. This acute attenuation of wakefulness and NREM sleep is 
consistent with a previous study in rats which demonstrated that interperitoneal (i.p.) 
administration of mepyramine during the light phase decreased wakefulness and increased 
NREM sleep in the two hours after dosing (Monti et al., 1986).  The short duration of the 
mepyramine-induced sedation could be explained by its rapid metabolism and elimination 
from the rat. The plasma elimination half-life of 0.7mg/kg mepyramine has been calculated to 
be approximately 2.3 hours (Kelly and Slikker, 1987). The circadian time at which mepyramine 
was dosed will also affect the extent of sleep promoting activity, since the CT-5 time used here 
was the middle of the animals light period during which more naturally occurring sleep is 
present.  In support of this, a previous study conducted within the laboratory demonstrated 
that i.p. administration of 20mg/kg mepyramine at CT-18 produced a more robust attenuation 
of NREM sleep (personal communication, Lilly) lasting up to four hours after dosing. Similar to 
results presented here, the average length of sleep bout was increased while REM sleep 
remained largely unaffected. The more robust increase in NREM sleep after CT-18 dosing is 
unsurprising given there is less naturally occurring sleep. A confounding factor here is the 
possibility that mepyramine may be more slowly absorbed and distributed differently when 
dosed i.p. (versus i.v. at CT-5). Unfortunately it was not possible to dose animals intravenously 
at CT-18 given the dark conditions, even red light would be permit i.v. dosing. A small but 
significant drop in body temperature was also observed after mepyramine administration. This 
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effect is observed with the application of other sedatives (personal communication) and is 
most likely related to the increase sleep and lack of movement just after drug dosing.  
 
5.4.3 Clinical significance of H1 inverse agonists on the sleep-wake cycle 
 
Although originally classified as antagonists, all clinically available antihistamines are in fact 
inverse agonists (Leurs et al., 2002). Antihistamines are most frequently used as first line 
therapeutics for allergic disorders. Sedation is one of the most common side effects of 
prescription and over-the-counter antihistamines. Clinically available antihistamines have 
been divided into different classes depending on their sedative properties; sedative (first 
generation) and less sedative (second generation) (Yani et al., 1995, 2007). First generation 
antihistamines, which include diphenhydramine and chlorphenamine, produce the most 
profound sedation due to ease with which they cross the blood brain barrier (Goldberg et al., 
1987). Second generation antihistamines, which include loratadine and fexofenadine, do not 
to cross the blood brain barrier as easily and hence produce much less sedation than the 
classical antihistamines (Izumi et al., 2008). The sedative properties of H1 inverse agonists are 
obvious however the constitutive activity of H1 receptors have not been demonstrated in vivo. 
It will therefore be important to assess the effect of H1 neutral antagonists on sleep 
parameters, especially given the demonstration that H1 receptors are constitutively active in 
vitro (section 4.6). Neutral H1 antagonists may present a novel method by which sedation 
could be safely achieved in humans. Given the recent availability of selective neutral 
antagonists, it is only a matter of time before these studies are performed.  
 
Conclusions and future directions 
 
This study has characterised the regulation of serotonergic DR neurons by a number of 
different neurotransmitter systems including: serotonin, noradrenaline, orexin and histamine. 
Ninety-five percent of neurons were shown to be inhibited by 5-HT in a concentration-
dependent manner, an observation in keeping with a plethora of evidence in the literature. An 
inhibitory role for 5-HT2 receptors was demonstrated, an effect which could have been 
mediated by GABA directly on 5-HT neurons. Given the low experiment numbers reported 
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here, it would be pertinent in future to produce more data confirming the inhibitory role of 5-
HT2 receptors in the DRN. Phenylephrine was shown to excite serotonin neurons in the DRN 
suggesting an important regulatory role for α1 adrenoreceptors. It will be interesting to 
investigate this excitatory drive further to assess whether it is specific to certain populations of 
5-HT neurons located in the DRN. Orexins were shown to have a robust excitatory influence on 
serotonin neurons in the DRN. Patch-clamp electrophysiology revealed that orexin induced a 
large inward current in all neurons tested however the second messenger system and 
downstream receptor responsible for this effect was not determined. While some evidence is 
available to suggest the involvement of a TRP channel, future studies should aim to better 
characterise the cellular mechanisms responsible for the orexin-induced excitation. Histamine 
was shown to have a strong and robust excitatory effect on 5-HT neurons in the DRN. Patch-
clamp recordings demonstrated that histamine depolarised neurons, caused a large inward 
current and increase in the baseline noise. Pharmacological studies revealed that H1 receptors 
were primary responsible for the histamine effect. Patch clamp recordings also demonstrated 
that these receptors were located on 5-HT neurons and suggested for the first time that H1 
receptors are constitutively active in the DRN. Further evidence to confirm the constitutive 
activity of H1 receptors in vitro is however needed. In vivo electrophysiology confirmed that H1 
receptors had an excitatory role in the DRN and demonstrated that these receptors are 
functionally active in the whole brain. Unfortunately the constitutive activity of H1 receptors 
was not explored in vivo. It will be important to demonstrate whether H1 receptors are 
constitutively active in vivo, especially as there is currently no report of this activity in the 
whole brain. EEG recordings revealed that inhibition of H1 receptors led to an increase of 
NREM sleep. This is in keeping with scientific and clinical data but raises an important question 
as to whether constitutive H1 receptor activity may play an important role in the increase of 
NREM sleep. Future studies should aim to investigate what effect neutral H1 antagonists have 
on sleep parameters in order to ascertain if these compounds could have a more clinically 
significant therapeutic benefit over currently available sleep medications.   
 
Collectively, the findings presented here demonstrate the regulation of serotonergic neurons 
in the DRN is multifactorial and highly complex. The data suggest for the first time the 
presence of constitutively active H1 receptors in the DRN. This constitutive receptor activity 
could have important implications for drug discovery. Combination sleep therapies which 
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target both the histamine and serotonin systems (e.g. H1/5-HT2 antagonists) could have less 
desirable efficacy than one may expect from their individual sedative actions. 
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